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ABSTRACT 
 
 The killer peptide sequence D-(KLAKLAK)2 has been originally designed and developed 
as an antibacterial agent. Despite having excellent cytotoxicity towards bacteria, this sequence 
maintains low cell cytotoxity in malignant mammalian cell types such as cancer. The chemical 
basis for its selectivity has been attributed to its poly(cationic) amphiphilic nature, which facilitates 
cell permeability across the negatively charged bacterial membrane, but with limited permeability 
across the zwitterionic membrane of mammalian cells. The positively charged D-(KLAKLAK)2 
sequence has been found to accumulate on the surface of the mitochondria causing dissipation of 
the negatively charged mitochondrial membrane potential. This charge disruption results in 
membrane lysis and the secretion of cell death markers that ultimately lead to programmed cell 
death. In order to overcome the limited activity of the D-(KLAKLAK)2 sequence in malignant 
tumor cell types, we proposed that chemically robust and structurally pre-organized amphiphilic 
nucleolipids would function to enhance cell permeability and mitochondria localization in tumors, 
resulting in potent and long-lasting anti-cancer effects. In this study, thymidine-derived 
nucleolipids were rationally designed to contain 3’-lipid appendages and a reactive 5’-carboxy 
group. A diversity oriented synthesis approach featuring a reductive amination procedure was 
developed for making a small library of amphiphilic nucleolipids. Solid phase bioconjugation 
coupled the nucleolipids with the pro-apoptotic D-(KLAKLAK)2 sequence for exploring structure-
activity relationships. The peptide nucleolipid conjugates were found to self-assemble into 
amphiphilic nanoparticle formulations that promoted anti-cancer activity in a selected panel of 
cancer cells. This thesis will serve to highlight the most important findings towards the 
development of peptide-nucleolipid conjugates that effectively serve as potent anti-cancer agents. 
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CHAPTER 1. BIO-ACTIVE PEPTIDES:  AN OVERVIEW OF THEIR 
STRUCTURE-FUNCTION RELATIONSHIP FOR ANTI-CANCER 
ACTIVITY 
 
1.1 ABSTRACT 
Biologically active peptides exhibit a variety of beneficial effects, including anti-proliferative, 
antioxidant, anti-microtubule, and antibacterial properties. Their isolation from natural sources e.g. 
plant and marine sources, including algae and cyanobacteria have led to the development of many 
antibiotic and anti-cancer drugs. Vancomycin is among the most famous examples. Bioactive 
peptides have also been isolated as secondary metabolites derived from sponges, ascidians, 
tunicates and mollusks. For example, protein hydrolysates derived from the enzymatic digestion 
of aquatic and marine by-products are an important source of bioactive peptides. These exhibit 
antioxidant, antimicrobial activities and cytotoxic effects on malignant mammalian cancer types 
such as HeLa, AGS, and DLD-1 cells. Key to their biological activity are various amino acid 
residues that may be naturally occurring or modified, in addition to the incorporation of ions, small 
molecules and transition metal ligands that can tailor the structure-function properties of the 
peptides. An important class of biologically active peptides belong to the amphiphilic, -helical 
cell penetrating peptides (CPPs). CPPs internalize within cells and traffic within endosomes until 
endosomal escape contributes to their delivery to various organelles. A common subcellular target 
for the positively charged CPPs is the negatively charged membrane surface of the mitochondria. 
Upon binding, depolarization of the negatively charged (-180 mV) mitochondrial membrane 
results in a loss of mitochondrial membrane integrity that stimulates the release of mitochondrial 
contents into the cytoplasm. The release of cell death effectors from the mitochondria, including 
cytochrome c, second mitochondrial derived activator of caspase and the apoptosis-inducing factor 
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(AIF) ultimately trigger programmed cell death. These desirable structure-function properties has 
led to the development of a new class of mitochondria penetrating peptides (MPPs) that exhibit 
potent activity against chronic diseases such as cancer.  
1.2 INTRODUCTION 
Short bioactive peptide sequences may exhibit efficient cellular uptake in mammalian cell 
types. These cell-penetrating peptides (CPPs) tend to have distinct structure-function properties. 
They include amphiphilic primary sequence compositions that typically include hydrophobic and 
positively charged amino acid residues. Moreover, the secondary structures of CPPs tends to be 
-helical in nature. The amphiphilic peptide sequence has been shown to contribute to membrane 
affinity and translocation activity. Moreover, the -helical peptide structure that has been found 
in many membrane spanning pore proteins has also been correlated as a secondary structure motif 
conducive to membrane transport and intracellular localization of soluble analytes [1]. A variety 
of cell translocation mechanisms have been attributed to the CPPs, including receptor and non-
receptor mediated endocytosis, micro- and pinocytosis which encapsulates the peptides in 
membrane-bound endosomes for intracellular trafficking and release at the targeted site for activity 
[2]. A common target for the CPPs is the mitochondrion. The mitochondrion is a key organelle 
that performs essential cellular functions and plays pivotal roles in regulating cellular metabolism, 
senescence and survival. Thus, the mitochondria represents an entry point of interest for organelle-
specific delivery of effector molecules used to treat metabolic, degenerative and hyperproliferative 
diseases [3]. In spite of their utility, mitochondria-targeting drugs remain hampered by a variety 
of side effects that limit their potential clinical utility. Therefore, the discovery of new drug-like 
molecules used to target the mitochondria in diseased cells and tissues is currently an urgent, un-
met need. Towards this end, a series of short, amphiphilic peptides that penetrate the plasma 
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membrane and localize within the mitochondria for biological activity have served as promising 
leads. For example, the Tat peptide, (Figure 1.1) derived from the HIV transactivator protein is 
considered one of the first representative examples of a mitochondria-penetrating peptide (MPP) 
[4]. 
 
Figure 1.1. Primary sequence of the HIV-Tat peptide (48-60), GRKKRRQRRRGYKC, as a 
representative mitochondria-penetrating peptide. Figure adapted from reference Green, M., 
Loeweinstein, M. Cell, 1988, 55, 1179 – 1188. 
         Once internalized within cells, MPPs accumulate on the surface of the mitochondria and 
induce depolarization of the mitochondrial membrane. This depolarization commonly results in 
cell apoptosis [5]. For example, the depolarization and disruption of the mitochondrial membrane 
results in the release of the cell death markers such as the apoptosis inducing factor (AIF).  
Additionally, Ca2+ flux plays an important role for VDAC mediated calcium ion signaling. In 
compromised cells, unregulated Ca2+ flux leads to the release of caspase co-factors needed for the 
pro-apoptotic activity of the caspase enzymes. Similarly, the calcium signaling receptor- BCL-2 is 
a class of proteins found exclusively on the cell surface of the mitochondria that regulates cell 
death events [5]. The BCL-2 family of proteins constitutes a critical checkpoint in the apoptotic 
cascade. BAX, BH3, BAK are also pro-apoptotic checkpoints functioning with BCL-2 at the 
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mitochondrial membrane [6]. In cells with damaged mitochondria, BCL-2 signaling triggers the 
release of pro-apoptotic executors, including cytochrome c and reactive oxygen species.  The 
formation of reactive oxygen species (ROS) aberrantly oxidizes biological molecules, altering 
their structure-function properties that ultimately impedes their normal cellular function [7]. Under 
these so-called “stressed conditions” protein misfolding also occurs and the unfolded-protein 
response (UPR) either rescues these proteins through chaperone activity or signals the release of 
caspase enzymes as pro-apoptotic executors in the absence of protein salvaging. Taken altogether, 
MPPs that serve to disrupt mitochondria structure and function can ultimately lead to programmed 
cell death by a variety of cell death signaling pathways (Figure. 1.2). 
In order to improve the structure-function properties of the MPPs, small molecule and 
biological ligands that effectively target selected cell types and accumulate within the 
mitochondria have been developed. Small molecule ligands such as triphenylphosphine (TPP) and 
choline esters incorporated within MPPs improved their inner mitochondrial membrane (IMM) 
localization properties. For the incorporation of IMM-specific biologicals, including 
phospholipids, gramicidin S (GS)-based antioxidants have also improved activity, with the 
concomitant delivery of nitroxide ROS scavengers into the cellular matrix [8]. Organometallic 
complexes e.g. metalloporphyrin-MPP conjugates (Figure. 1.3), have also been developed as  
antioxidants within the mitochondria [9]. For example, the Mn-porphyrin-peptide stimulated 
superoxide dismutase (SOD) activity and decomposed peroxynitrite (ONOO-), effectively 
scavenging NO-mediated apoptosis that resulted in increased cell viability in lipopolysaccharide 
[10] (LPS) stimulated macrophages RAW 264.7 cells. 
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Figure 1.2. Possible cell death pathways triggered by the mitochondrial-targeting peptide D-
(KLAKLAK)2. Figure adapted from Farsinejad, S.; Gheisary, Z.; Ebrahimi, S.; Mohammad, A.A. 
Tumor Bio, 2015, 36, 5715-5725. 
 
           Short synthetic peptides that correspond to the BH3 pro-apoptotic effector domains e.g. 
BIDBH3 peptide sequence: EDIIRNIARHLAQVGDSMDR and BIMBH3 peptide sequence: 
MRPEIWIAQELRRIGDEFNA have also been designed and developed. These so-called “killer 
peptides” initiate the cell death cascade either by activating pro-apoptotic members or by 
counteracting anti-apoptotic members by displacing BH3 antagonists from their binding domains 
[11]. These killer peptides have been shown to trigger cell death in Jurkat leukemic cells. 
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Figure 1.3 Chemical structure of Mn-porphyrin modified with the mitochondria signaling peptide. 
Figure adapted from reference: Asayama, S., Kawamura, E., Nagaoka, S., Kawakamli, H. Mol. 
Pharm., 2005, 3, 468-470. 
 
1.3 D-(KLAKLAK)2 ANTIMICROBIAL PEPTIDE: SYNTHESIS, 
CHARECTERIZATION AND BIOLOGICAL ACTIVITY. 
 The pro-apoptotic peptide D-(KLAKLAK)2 is an antimicrobial peptide having the ability 
to internalize within bacteria and disrupt the mitochondrial membrane (Figure 1.4) [12]. The pro-
apoptotic domain of the D-(KLAKLAK)2 sequence is amphiphilic in nature and composed of 
hydrophobic leucine and alanine residues and with positively charged lysines. Moreover, in 
aqueous media, the peptide was found to adopt an -helical secondary structure. These properties 
were found to be contributive to the biological activity of the peptide sequence, which readily 
penetrated the bacterial cell membrane. Inside cells, the peptide localized and disrupted the 
mitochondria leading to the selective cell death in bacteria and to a much lesser extent in 
mammalian cells. This selective activity is partly due to the higher affinity of the positively charged 
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D-(KLAKLAK)2 peptide to the negatively charged bacteria cell surface, but to a lesser extent to 
the more neutral and hydrophobic composition of the mammalian cell surface [13]. 
 
 
Figure 1.4. Primary sequence of the antimicrobial D-(KLAKLAK)2 peptide at physiological 
pH=7.4. Figure adapted from reference Javadpour, M.M.; Juban, M.M.; Lo, W.C.; Bishop, S.M.; 
Alberty, J.B.; Cowell, S.M.; Becker, C.L.; McLaughlin, M.L. J. Med. Chem. 1996, 39, 3107-
3113. 
In order to improve the biological activity of the D-(KLAKLAK)2 peptide within malignant 
mammalian cell types, cancer targeting peptides (CTP) or monoclonal antibodies have been 
incorporated to target and internalize the killer peptide sequence in cancer cells. For example a 
peptide comprised of a protein transduction domain (PTD), PTD-5, fused to an antimicrobial 
peptide, D-(KLAKLAK)2 was able to trigger rapid apoptosis in a variety of cell lines in vitro. This 
included the MCA205 murine fibrosarcomas, the human head and neck tumors. A multifunctional 
theranostic nanoparticle has also been reported, where the CGKRK peptide provides the targeting 
function that takes the nanoparticles to tumor vascular cells and into their mitochondria. The 
nanoparticle uses the mitochondria-targeted D-(KLAKLAK)2 peptide as the drug and iron oxide 
as a diagnostic component for MRI [14, 15].  
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In this study, the D-(KLAKLAK)2 will be synthesized using the Fmoc-Solid Phase Peptide 
Synthesis (Fmoc-SPPS) method [16]. Upon completion of the synthesis cycle, the crude peptide 
will be analyzed and purified by reverse phase high performance liquid chromatography (RP 
HPLC). Characterization studies will be performed by electrospray ionization mass spectrometry 
(ESI MS) to confirm molecular weight identity. The biophysical and structural properties will be 
respectively analyzed by a combination of ultraviolet-visible (UV-Vis) and circular dichroism 
(CD) Spectroscopy. These structure-function relationships are important determinations for 
elucidating the biological activity of the killer D-(KLAKLAK)2 peptide sequence and its 
conjugates within malignant cancer cell types.  
1.3.1 SYNTHESIS AND CHARACTERIZATION OF D-(KLAKLAK)2. 
Solid phase peptide synthesis (SPPS) has been recognized as the most widely used 
technique for making short and long chain peptide sequences with natural and unnatural amino 
acids [17]. The use of an insoluble resin is key to this efficient method and provides a solid support 
for growing peptide sequences following coupling and deprotection steps of Fmoc-protected 
amino acids (Scheme 1.1). 
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Scheme 1.1. Schematic diagram of the Fmoc-based solid phase peptide synthesis cycle. Synthesis 
cycle based on Behrendt, R.; White, P.; Offer, J. J. Pept. Sci. 2016, 22, 4-27. 
  
The SPPS method was first invented by Nobel laureate Bruce Merrifield following the 
synthesis of the short peptide (LAGV) on polymer beads [18]. Since then, many short and long 
peptide sequences, including our target, D-(KLAKLAK)2, have been synthesized for a wide range 
of applications in biology, chemistry and in medicinal chemistry [17]. The careful selection of the 
insoluble solid support (resin) is a crucial first step to a successful peptide synthesis strategy. The 
Merrifield-based polystyrene resin was first used in the synthesis of short peptide sequences.  
However, this solid support proved challenging for making lengthier, more hydrophobic peptides 
that aggregated during the course of peptide synthesis limiting coupling and deprotection 
efficiency. Consequently, new and improved resins, including the, TentaGel and NovaPEG resins 
[19,20] modified the polystyrene support with polyethylene glycol (PEG), (Figure 1.5). The 
incorporation of PEG improved the polar properties of the Merrifield resin, providing it with 
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greater swelling capabilities in N,N-dimethylformamide (DMF), the solvent of choice for SPPS 
[20]. In addition, a suitable linker is incorporated in between the resin and the peptide sequence. 
The linkers are especially useful for anchoring amino acids onto the solid support for peptide 
synthesis but also for modifying the C-terminus of the sequence. For example, the Rink amide 
linker has been incorporated for the generation of C-terminal peptide amides whereas the Wang 
resin incorporates a linker that affords C-terminal peptide acids (Figure 1.5) [21]. Moreover, these 
linkers also facilitate the removal of the peptide sequence from the solid support, which is typically 
accomplished using concentrated trifluoroacetic acid (TFA) as opposed to the toxic hydrogen 
fluoride (HF) gas initially used for the removal of peptides from the Merrifield resin. 
 
Figure 1.5. Solid supports and linkers for Fmoc-SPPS.  Rink amide (RL) or Wang linked (WL) 
polystyrene-divinylbenzene (PS-DVB) 1.1) Rink amide-linker polystyrene-graft-poly(ethylene 
glycol) resin (Tenta Gel, 1.2) poly(ethylene glycol) (NovaPEG, 1.3) Wang resin linker with solid 
support. 
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Following the judicious selection of an insoluble polymer support, and removal of the 
fluorenylmethoxycarbonyl (Fmoc) protecting group using piperidine as a base, the linker-bound 
support is ready for peptide synthesis. The N- Fmoc amino acids require orthogonal protection of 
side chain functional groups with TFA-labile protecting groups (e.g. Boc).  A reactive coupling 
reagent effects the efficient coupling of amino acids to the linker-bound solid support. This 
coupling step typically functions to convert the C-terminal carboxylic acid to a reactive ester which 
favors coupling to the amino (peptide amides) or hydroxyl (peptide acids) groups on the solid 
support. Moreover, coupling reagents also facilitate the key peptide bond forming reactions 
between the N-terminal peptide bound support and the C-terminal active ester of the coupling N-
Fmoc amino acid. Many coupling reagents for SPPS have been reported, including the 
carbodiimide-based couplings [22]. More reactive reagents for coupling have been developed to 
shorten the coupling times of N-Fmoc amino acids. These are particularly based on the uronium 
coupling reagents, such as,  O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HCTU) which worked particularly well in the solid phase synthesis of 
challenging peptides with coupling times as short as 1 minute [23]. 
 The coupling procedure is followed by an Fmoc deprotection step, in which a secondary 
alkylamine is used to effect the elimination of the Fmoc group without concomitant epimerization 
of the peptide-bound support. Towards this goal, dilute solutions of alkylamines (i.e. 20% 
piperidine or 4-methylpiperidine in DMF, 10% piperidine in EtOH/NMP, 10:90 v/v, and 
piperazine/DBU) have been used to effectively un-mask the N-terminal amino groups for Fmoc-
SPPS [24]. These steps have been incorporated within fully automated peptide synthesizers with 
and without microwave heating for rapid and high yielding coupling and deprotection steps. 
Following synthesis, cleavage of the peptide from the solid support and deprotection of side-chain 
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protecting groups are typically accomplished with concentrated trifluoroacetic acid (TFA) with 
minimal addition (<5%) of reaction scavengers (i.e. H2O, triethylsilane, phenol and anisole). These 
conditions minimize side-product formation and improve yields of the crude peptide in solution 
for analysis and purification by RP HPLC. The identities of the isolated peptides are then 
confirmed by molecular weight analysis using ESI MS. With pure peptides in hand, structure-
function properties are then investigated by a combination of spectroscopy, microscopy and 
chromatography for potential biological applications.  
1.3.2 FMOC-SOLID PHASE PEPTIDE SYNTHESIS OF THE D-(KLAKLAK)2 
SEQUENCE 
 The goal of this study was to synthesize the antimicrobial killer peptide sequence D-
(KLAKLAK)2 by Fmoc-SPPS. Synthesis of this cationic peptide required the use of the PEGylated 
ChemMatrix Rink amide resin with a loading capacity of 0.47 mmol/g.  A quantity of resin (300 
mg) was used for a 0.1 mmol scale peptide synthesis that was anticipated to yield ~30-50 mg of 
the desired peptide sequence, sufficient for our structure-function relationship studies. Peptide 
synthesis was conducted either in a semi-automated PSI 200C Peptide Synthesizer (Fairfield, NJ) 
or within plastic PolyPrep cartridges. The resin was initially swollen in DMF and the addition of 
Fmoc-amino acids (3eq.), HCTU as coupling reagent (3eq.), NMM as base (6 eq.) and DMF as 
solvent (4-6 mL) were added to the resin to initiate the coupling reactions (Scheme 1.2). Typically, 
HCTU mediated coupling reactions of Fmoc-amino acids reach completion in 20-30 minutes at 
room temperature, while elevated temperatures (50-60 oC) and microwave irradiation allows for 
much faster reaction times, on the order of 2-5 min [25]. Coupling reactions for the D-
(KLAKLAK)2 sequence conducted at room temperature in order to minimize the likelihood of 
epimerization and side reactions at elevated temperatures [26]. Following coupling of Fmoc amino 
acids, deprotection of the N-terminal of Fmoc group was accomplished using basic piperidine in 
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DMF (20% piperidine in DMF, 4 mL). Complete Fmoc deprotection typically required successive 
additions of the piperidine reaction mixture. An initial treatment for 3-5 min removes most of the 
Fmoc group while a second, longer reaction for about 15 min was used to remove the remaining 
quantities of protecting group [20]. At the liberated N-terminus, coupling reactions were continued 
and followed by Fmoc deprtections until the desired, full-length peptide sequence was made on 
solid phase Scheme 1.3.    
 
Scheme 1.2. HCTU activation of Fmoc-amino acids. Fmoc protected amino acid (1.5) reacts with 
the HCTU coupling reagent (1.6) and the base, N-methylmorpholine (NMM), to form the activated 
Fmoc-amino ester (1.7). 
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Scheme 1.3. Fmoc-SPPS of the D-(KLAKLAK)2  peptide sequence.  
 
Following peptide synthesis on solid phase, the cleavage and deprotection steps released 
the peptide from the solid support and removed all side-chain protecting groups. The cleavage and 
deprotection steps are effected by TFA (95%, 1-3 mL) with TES (2.5%, 25-75 L) and water 
(2.5%, 25-75 L) scavenging reactive intermediates. The cleavage and deprotection cocktail was 
concentrated under a stream of inert nitrogen. The crude peptide was then precipitated with cold 
ether (5-10 mL), vortexed and centrifuged to remove the supernatant and the crude peptide was 
isolated as a solid, white pellet, which washed twice more with cold ether. The crude peptide pellet 
was dried in vacuo and then resuspended in a mixture of MeCN:H2O (1 mL, 50:50 v/v) with 
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minimal addition of an ion-pairing reagent (0.1% TFA or FA) to enhance dissolution for LC/MS 
analysis and purification.  
1.3.3. ANALYSIS AND PURIFICATION OF D-(KLAKLAK)2 SEQUENCE BY LC/MS  
 Following peptide synthesis, peptide crude purity and identity was assessed by LC/MS. A 
Waters C18 symmetry shield column, (5.5 M, 4.6 x150 mm) was used for the separation analysis. 
Moreover, an eluent gradient composed of: 2-83% MeCN or MeOH in water with (0.1% TFA) 
over 18 min was used for efficient peptide separation on the reverse phase column. Reaction 
progress was followed at 220 nm for amide bond absorptions using a photodiode array (PDA) 
detector. The crude peptide demonstrated a purity of 69% (Figure 1.6), while the purified peptide 
produced an isolated purity of >90% (Figure 1.7). The observed crude impurities were primarily 
due to failure sequences that accompanied incomplete coupling reactions of Fmoc-amino acids 
Figure 1.6. Following purification by RP-HPLC, the isolated peptide was found to have a purity 
of 93% in multiple eluent conditions composed of MeOH or MeCN in water and TFA (Figure 
1.7). In order to confirm the identity of the purified, isolated peptide, ESI MS validated the 
molecular weight of the D-(KLAKLAK)2 sequence, without detection of any significant impurities 
(Figure 1.8). The pure peptide was freeze-dried and lyophilized to dryness, stored in the freezer 
until further use.   
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 Name Retention Time Area % Area 
1  4.970 672853 13.43 
2  6.337 3456296 69.00 
3  6.994 255399 5.10 
4  7.866 285856 5.71 
5  8.356 192441 3.84 
6  8.962 146376 2.92 
 
Figure 1.6. RP-HPLC chromatogram of the crude D-(KLAKLAK)2. Linear gradient 2-83% 
MeOH (0.1% FA) over 18 min, with  YMC Column-C18, (4.6 x 250 mm, 5.0 µm particle size) at 
25 °C and flow rate of 1.0 mL/min with detection at 220 nm. 
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 Retention Time Area % Area Height 
1 5.727 40407 0.84 16862 
2 5.828 71105 1.49 28974 
3 6.049 108374 2.26 40163 
4 6.190 51206 1.07 20630 
5 6.835 65376 1.37 28942 
6 6.987 4448515 92.97 998144 
 
Figure 1.7. RP-HPLC chromatogram of the purified D-(KLAKLAK)2. Linear gradient 2-83% 
MeOH (0.1% FA) over 18 min, with  YMC Column-C18, (4.6 x 250 mm, 5.0 µm particle size) at 
25 °C and flow rate of 1.0 mL/min with detection at 220 nm. 
 
Figure 1.8. ESI –MS spectra of the purified, isolated D-(KLAKLAK)2. MSD signal parameters: 
Threshold: 150, Step size: 0.15, Mode: scan, Polarity: Positive, Mass range: 500 to 3000, 
Fragmentation: 70, Gain: 1.0, Source: API-ES, Peak width: 0.10 min, Cycle time: 0.98 sec/cycle. 
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1.3.4 CHARECTERIZATION OF THE D-(KLAKLAK)2 SEQUENCE BY CIRCULAR 
DICHROISM SPECTROSCOPY  
Circular Dichroism (CD) spectroscopy provides important structural information of 
optically active chromophores over a wavelength range that is typically in the UV region (190-360 
nm). CD spectroscopy aims to study chiral molecules of all types and sizes, but is used extensively 
in the study of large biological molecules, including in the determination of peptide structures. In 
relation to peptides, CD spectroscopy provides characteristic spectral traces that are consistent 
with peptide secondary and some tertiary structure arrangements. For example, peptide random 
coils or disordered structures exhibit a strong minimum band at 190 nm. Alternatively, ordered 
peptide secondary structures such as the -helix (maximum at 190 nm, minima at 210, 230 nm), 
the -sheets and turns (maximum at 200 nm, minimum at 220 nm) exhibit characteristic Cotton 
effects that helps distinguish between different types of secondary structures (Figure 1.9). These 
studies are also useful in determining structure, kinetics and thermodynamic stability of peptides 
in a wide range of solvent, pH and temperature conditions.  
  
Figure 1.9. CD spectra and secondary peptide structures.  The CD spectrum of poly-L-lysine in α-
helix, -sheet, and disordered (random coil) structures. 3D structural representation of 
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corresponding peptide secondary structures and random coils. Figure adapted from Dr. Ramy S. 
Farid- Discussion of CD Spectroscopy, a revised version of online lecture notes. 
 
In this study, the structural properties of the isolated, pure D-(KLAKAK)2 sequence was 
investigated on an Aviv Circular Dichroism (CD) Spectrophotometer (Model: 62A DS). The 
peptide samples (30 – 220 M) dissolved in phosphate buffered saline (PBS), (8 g of NaCl, 0.2 g 
of KCl, 1.44 g of Na2HPO4, 0.24 g of KH2PO4, adjusted the pH to 7.4 with HCl, dissolved in 1 L 
of distilled H2O). The CD spectra of the D-(KLAKAK)2 sequence was collected from 190-260 nm 
using 1 nm bandwidth and 0.5 min step size at with 30 spectra points at 25 oC. Triplicate 
measurements were collected separately to ensure uniformity and reproducibility of the results.  
Spectra were blank corrected, smoothed and data converted to molar ellipticity values from the 
equation [θ] = θ /cl, where θ is the relative ellipticity (mdeg), c is the molar concentration of the 
peptides (µM) and l is the path length of the cell (1 cm). The data was imported into Microsoft 
Excel and the CD spectra plotted in terms of molar ellipticity vs. wavelength. 
 CD spectroscopy of D-(KLAKLAK)2 sequence revealed a peptide sequence that exhibits 
α-helical character at lower (30 M) concentration ranges that are expected to be physiologically 
relevant. At lower concentrations, the CD spectra suggests an -helical peptide structure according 
to the minima observed at 210 and 230 nm with a strong maximum band apparent at 190 nm 
(Figure 1.11). Many α-helical proteins are present in the inner membranes of bacterial cells or the 
plasma membrane of eukaryotes, and sometimes in the outer membrane. They function as a major 
structural component of transmembrane proteins that facilitates the passage of molecules and ions 
in and out of the cell (i.e. transporter proteins). Interestingly, at higher concentrations (>100 M) 
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the D-(KLAKLAK)2 sequence is seemingly transitioning to a -sheet or turn conformation with a 
strong negative band detected at around 230 nm and a positive one at around 200 nm (Figure 
1.10). These results suggests the D-(KLAKLAK)2 sequence contains a flexible secondary 
structure, capable of transitioning between different conformations as a function of concentration. 
This trend is anticipated to persist in different conditions, including variations in solvent, pH, ion 
strength and temperatures. 
 
 
 
 
Figure 1.10. CD Spectra of the D-(KLAKLAK)2 peptide sequence (30 – 120 M) in PBS buffer. 
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1.4 BIOLOGICAL ACTIVITY OF D-(KLAKLAK)2 SEQUENCE IN BACTERIA AND 
MAMMALIAN CELLS  
 Some antimicrobial peptides selectively inhibit and kill bacteria while maintaining low 
mammalian cell cytotoxicity [27]. This selectivity can be attributed to the membrane differences 
between bacteria and mammalian cell types. The exterior membranes of bacteria tend to be 
predominantly negatively charged due to a composition of anionic phospholipids and glycolipids. 
The mammalian cell exterior membranes are generally neutral in charge due to a mixed 
composition of complex biologicals, including the neutrally charged sphingolipids and cholesterol. 
Consequently, the positively charged D-(KLAKLAK)2 sequence was found to have higher binding 
affinity and biological activity in bacteria vs. mammalian cell types.  
Interestingly, the amphiphilic peptide sequence and -helical secondary structure were also 
found to contribute to its cell translocation mechanism and localization onto the mitochondria. At 
the localized organelle, the peptide sequence was found to disrupt the mitochondria membrane 
integrity and biological function leading to its cytotoxic activity. Moreover, peptide translocation 
was postulated to occur by membrane fusion and translocation into the cytosol via endosomal 
transport and escape [14,15,28]. Alternatively, a receptor-mediated endocytic pathway was 
reported with the incorporation of a targeting vector or homing domain specific for a cell surface 
protein receptor (Figure 1.11) [29-33]. The latter is a crucial requirement for improving the 
mammalian cell cytotoxic activity of the D-(KLAKLAK)2 sequence.  
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Figure 1.11. Schematic description of cell permeability and cytotoxicity of the D-(KLAKLAK)2 
sequence in bacteria and mammalian cell types. 
 
1.5 DESIGN, SYNTHESIS, AND ANTI-CANCER ACTIVITY OF THE D-(KLAKLAK)2 
BIOCONJUGATES. 
 In order to enhance the cytotoxic activity of the killer D-(KLAKLAK)2 sequence in 
malignant mammalian cell types, such as in cancers, modifications to the primary sequence 
composition and bioconjugation with small molecules, biologicals and cytotoxic drugs have been 
incorporated [14,15,28]. For example, a new dual-targeting pro-apoptotic peptide (DTP) was 
synthesized, characterized and evaluated for anti-cancer activity [29].  
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Figure 1.12. Dual targeting pro-apoptotic peptide and mechanism of action for the amphiphilic 
peptide: TPP-KFA-D-(KLAKLAK)2. Figure adapted from reference Chen, W.H. et. al. Sci. Rep. 
2013, 3, 3468. 
 
This peptide bioconjugate combined three components within its bioactive form. Namely, 
the folic acid (FA) moiety for targeting the folate receptor (FR) overexpressed on the surface of 
cancer cells that facilitates receptor-mediated endocytosis. The positively charged and 
hydrophobic triphenylphosphine (TPP) moiety, facilitates cell permeability and mitochondria 
localization for the cytotoxic activity of the D-(KLAKAK)2 sequence (Figure 1.12). This 
bioconjugate was synthesized by Fmoc-SPPS, isolated and characterized by LC/MS followed by 
its anti-cancer evaluation in KB, HeLa and COS7 cancer cells. Significantly, the bioconjugate was 
found to be more active than the native, D-(KLAKAK)2 sequence, underscoring the importance of 
homing and penetrating vectors for mammalian cancer cell cytotoxic activity.   
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In a related example, the pH sensitive pHLIP peptide (GGEQNPIYWARY 
ADWLFTTPLLLLDLALLVDADEGTCG) was linked via a reducible disulfide bond to the D-
(KLAKLAK)2 sequence [30]. The synthesis of the wild type (WT) pHLIP sequence was 
accomplished by Fmoc-SPPS with the incorporation of a reactive cysteine residue at its C 
terminus.  Subsequently, the D-(KLAKLAK)2 sequence was also synthesized by Fmoc-SPPS with 
a reactive cysteine at the N-terminus for coupling onto the pHLIP sequence by disulfide bond 
formation. The pHLIP-S-S-D-(KLAKLAK)2 bioconjugate was purified via reversed-phase high 
performance liquid chromatography (RP-HPLC). The purity of the peptides were determined by 
RP-HPLC, and their identities were confirmed via matrix-assisted laser desorption ionization time 
of flight mass spectrometry (MALDI-TOF-MS). Interestingly, the pHLIP peptide is a 36 residue 
sequence derived from the C helix of bacteriorhodopsin, a  transmembrane spanning protein, [31] 
and shows the ability to insert across the lipid bilayer and form a transmembrane helix at lower 
pHs found within the acidic tumor microenvironment [31]. Thus, the pHLIP sequence contains 
tumor homing capabilities that would facilitate the delivery of cytotoxic agents directly within 
tumors. This is because at a pH corresponding to the extracellular pH of tumors, the pHilip 
sequence undergoes a pH-dependent conformational change driven by the protonation of aspartic 
acid residues, promoting the insertion of its C-terminus across the cell membrane to form a 
transmembrane α-helix [32]. In this manner, the (KLAKLAK)2 sequence internalized within the 
cytosol of malignant tumor cells, such as, MDA-MB-231 breast cancer cell line and released by 
disulfide bond reduction by the reducing tumor cytosol for anti-cancer activity (Figure 1.13).  
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Figure 1.13. Schematic representation of the cell internalization and apoptosis activities of the 
pHilip–(KLAKLAK)2 sequence. Figure adapted from Burns, K. E., McCleerey, T. P., Thevenin, 
D. Sci. Rep., 2016, 6, 28465. 
 
In a final example, the cytotoxic peptide D-(KLAKLAK)2 conjugated to amphiphilic poly 
(β-thioester) copolymers were composed of ROS sensitive backbones and hydrophilic PEG side 
chains [33]. The conjugates were prepared by Fmoc-SPPS, and functionalization of the peptide 
onto the copolymer was accomplished by Michael addition of a reactive N-terminal Cys with the 
acrylate-derived copolymer backbone. In solution, the peptide-functionalized copolymer self-
assembled into micelle-type nanoparticles due to the hydrophobic interactions of the copolymer 
backbone with the PEG and D-(KLAKLAK)2 moieties (Figure 1.14). The self-assembled 
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polymer−peptide nanoparticles remarkably improved cellular internalization and accumulation of 
the therapeutic D-(KLAKLAK)2 sequence in cancer cells. Compared to the free KLA peptide, the 
anti-tumor activity of the peptide-copolymer conjugate was signiﬁcantly enhanced, up to ∼400 
times, suggesting the eﬀectiveness in cancer treatment applications. The higher antitumor activity 
of the nanoparticles was attributed to the eﬃcient disruption of mitochondrial membranes and 
subsequent excessive ROS production in cells. The ROS production around the mitochondria 
stimulated the swelling of nanoparticles and subsequent release of squaraine dyes. Squaraine 
dyes are a class of organic dyes showing intense fluorescence, typically in the near infrared region. 
They also form H-aggregates and signiﬁcantly contribute to photoacoustic (PA) signaling for 
imaging the effects of ROS generation in live cells. In this manner, the self-assembled polymer 
peptide nanotherapeutics may hold great promise in medicinal chemistry applications.  
 
Fig.1.14. Self-assembled ROS-sensitive polymer-peptide conjugate (PPC) incorporating a reporter 
for enhanced tumor treatment. Figure adapted from Qiao, Z. Y.; Zhao, W. J.; Cong, Y.; Zhang, D.; 
Hu, Z.; Duan, Z. Y.; Wang, H. Biomacromolecules, 2016, 17, 1643–1652. 
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1.6 NUCLEOLIPIDS: COMPOSITION, SYNTHESIS, CHARACTERIZATION AND 
APPLICATIONS IN CANCER THERAPY 
Nucleolipids are a special class of bioconjugates composed of a nucleoside and a lipophilic 
moiety e.g. alkyl chain, cholesterol, vitamin or fatty acid.  A representative example of a naturally 
occurring nucleolipid consists of cytidinediphosphate diacylglycerol. This nucleolipid is 
composed of cytidine diphosphate functionalized with a diacylglycerol moiety at the 5’-
diphosphate position. As such, the nucleolipid functions as a reactive intermediate for the 
functional group-transfer of the phosphatidic acid group. The nucleolipid is formed by the reaction 
of phosphatidic acid with cytidine-5-triphosphate resulting in the concomitant release of 
pyrophosphate (Scheme 1.4). By the transfer of the phosphatidic acid group onto OH groups of 
carbohydrates or proteins, glycolipids and lipoproteins are formed. Transfer to inosite or glycerol-
3-phosphate results in the formation of the membrane components phosphatidylinosite and 
cardiolipin. Thus, the nucleolipid cytidinediphosphate diglycerol functions as a reactive 
intermediate in the biosynthesis of phospholipids, such as phosphatidylinositol, and regulates 
lipid-dependent signal transduction pathways [34]. Considering their relevance in biology, 
chemical synthesis methods have been developed for generating new nucleolipids for potential 
therapeutic applications.     
 
Scheme 1.4. Biosynthesis of Cytidinediphosphate diglycerol. Figure adapted from Liu, X.; Yin, Y.; Liu, Z. Nature, 2014, 5, 
4244. 
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 1.6.1 AMINO ACYLNUCLEOLIPID  
 
The aminoacyl nucleolipids are an interesting class of synthetic amphiphilic nucleolipid 
bioconjugates. A variety of synthetic aminoacyl nucleolipids (Figure 1.15) have been prepared 
and found to self-assemble into higher-ordered biomaterials for applications in gene therapy, 
medicinal chemistry and biotechnology. These interesting properties stem from the amphiphilic 
nature of the bioconjugate, which readily self-assembles into high-order nanoparticle formulations 
or aggregates, which imparts its biological activity. For example, the synthetic guanosine 
aminoacyl nucleolipids (1.16, 1.17) displayed the ability to form stable G-tetraplexes (G-tetrads) 
in organic solvents [35], and were also found to behave as Li+ and K+ ion chelators. These materials 
were also found to facilitate transport of H+/OH ions in the presence of an applied pH gradient 
[36]. Moreover, aminoacyl nucleolipids, 1.16 and 1.17 showed moderate to weak activity (IC50: 
17 - >103 µM) in an anti-proliferative assay across a panel of five tumor cell lines underscoring 
their potential in biomedical applications [36]. In a related case study, a cationic aminoacyl 
surfactant (1.18) demonstrated micelle forming capabilities in water according to DLS studies and 
modest cell toxicities (IC50: 19 – 98 µM) relative to the cytotoxic cetyl triethylammonium bromide 
(CTAB) cationic amphiphile in a panel of human, rat and murine cell lines [37]. In light of their 
abilities to form stable cationic assemblies, the aminoacyl nucleolipids have been applied to gene 
delivery and treatment applications in-vitro [38]. The development of short interfering RNAs 
(siRNAs) have enabled the application of site-specific mRNA knockdown through the RNA 
interference (RNAi) pathway [34]. In spite of its potential in gene therapy applications, siRNAs 
remain limited by poor cell permeability. In an effort to overcome this limitation, siRNA delivery 
agents (transfection agents) have been developed to effectively condense and deliver siRNA across 
the amphiphilic cell membrane for RNAi activity.  
29 
 
 
Figure 1.15. Structures of synthetic aminoacyl nucleolipids.  
In this scope, a small library of synthetic  polycationic nucleolipids have been formulated 
for siRNA transfection within HeLa cells for potent Vascular Endothelial Growth Factor (VEGF) 
knockdown [38]. The spermine derived aminoacyl nucleolipid (1.19) exhibited comparable siRNA 
transfection efficiencies (>90% VEGF knockdown) and cell death (~20%) as the benchmark 
Lipofectamine-based siRNA transfections, underscoring the utility of nucleolipids as siRNA 
transfection vectors. Moreover, metabolically stable variants of aminoacyl nucleolipids (Figure 
1.15) have also been formulated for siRNA delivery applications in HeLa cells [39]. This cationic 
nucleolipid formed stable ionic complexes with anti-VEGF siRNA leading to potent VEGF 
knockdown (>90%) in HeLa cells [39]. These examples effectively demonstrate the fruitful 
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implementation of aminoacyl nucleolipids in condensing oligonucleotides and transporting them 
within cells for medicinal chemistry applications. 
In our contribution, an aminoacyl nucleolipid was based on a guanine nucleoside, which 
contains the ability to participate in H-bonding interactions, an aminoacyl group for potential ionic 
bonding, and lipids which enable the self-assembly through non-polar interactions (Figure 1.16) 
[40]. The aminoacyl nucleolipid designed and synthesized in our study was anticipated to interact 
favorably with the promoter sequence of the GRP78 oncogene. This proposed DNA binding ligand 
was expected to unleash potent anti-cancer effects in GRP78 overexpressing tumors.   
 
 
Figure 1.16. Chemical structure and DNA-binding interactions of an aminoacyl nucleolipid. 
Figure adapted from Patel, P.; Hanawa, E.; Yadav, R.; Samuni, U.; Marzabadi, C.; Sabatino, D. 
Bioorg. Med. Chem. Lett. 2013, 23, 5086-5090. 
 
 
Our study began with the solution phase synthesis of an aminoacyl nucleolipid building 
block, 1.28. The synthetic strategy involved the production of N-isobutyryl 5’-carboxy 2’,3’-bis-
O-(carbobenzyloxy) guanosine, 1.24, (Scheme 1.5). N-isobutyrroyl 5’-dimethoxytrityl guanosine, 
1.21, was used to attach the Cbz protecting groups with benzylchloroformate and DMAP in DCM. 
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Following carbomylation, 1.22, was detritylated using 3% trichloroacetic acid in DCM (3% 
TCA:DCM) affording the guanosie analog, 1.23, in 98% yield. N-isobutyrryol-2’,3’-bis-O-
(carbobenzyloxy)guanosine, 1.23, was then oxidized to the carboxylic acid, 1.24, in 82% yield, 
using  TEMPO oxidation.  
 
Scheme 1.5. Synthesis of N-isobutyryl 5’-carboxy 2’,3’-bis-O-(carbobenzyloxy) guanosine, 1.24. 
Conditions: (a) DMAP, benzyl chloroformate, DCM, 0o C then r.t., 72 h, 77%, (b) 3%TCA:DCM, 
r.t., 15 min, 98%, (c) TEMPO, BAIB, MeCN:H2O (50:50 v/v), r.t., 15 h, 82%. 
 
Fmoc-Lys(Boc) was coupled at the 5’-carboxy position of 1.24 using N-ethoxycarbonyl 
1,2-ethoxy-1,2-dihydroquinoline, EEDQ, (2 equiv) as coupling reagent and N,N-
diisopropylethylamine, DIEA (2 equiv) as the base in DMF. The reaction produced the desired 
product in >99% yields.  The Cbz protecting groups were deprotected using hydrogenolysis, 
generating diol 1.26 in quantitative yields (Scheme 1.6). The product was acylated with an excess 
of palmitoyl chloride to afford the protected aminoacyl nucleolipid 1.27 in >99% yield. The Boc-
protecting group of 1.27 was removed using 50% TFA:DCM, followed by salt exchange to the 
hydrochloride salt with aqueous HCl. The desired aminoacyl nucleolipid, 1.28, was obtained in 
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quantitative yields in this final reaction step and its purity and composition was ascertained by 1H 
NMR, 13C NMR, IR, UV/Vis, and MS techniques. A variety of experimental techniques, including 
gel shift mobility assays, thermal denaturation and CD spectroscopy were used to confirm the 
binding interactions of the aminoacyl nucleolipid with the GRP78 DNA. 
 
 
 
Scheme 1.6. Solution phase synthesis of aminoacyl nucleolipid. Conditions: (a) H2, 10% Pd/C, 
EtOH, r.t., 1.5 h, >99% (b) palmitoyl chloride, DMAP, pyr., 2 h, >99% (c) 50% TFA:DCM, 2 h, 
r.t., then 1 M HCl, 3 h, >99%. 
 
In order to assess the anti-cancer activity of the aminoacyl nucleolipid, a cancer cell line-
screening assay was conducted against a panel of 60 cell lines at the National Cancer Institute 
(NCI). A single dose (10 µM) test was performed with the synthetic aminoacyl nucleolipid and 
cell viability was determined following 48 h incubation with cancer cells. A sulforhodamine B 
(SRB) cell viability assay was performed to determine cell death activity. The aminoacyl 
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nucleolipid was found to exhibit potent (90%) and selective anti-cancer activity against a SR 
human lymphoblastic leukemia cancer cell line (Figure 1.17). Interestingly, GRP78 is 
overexpressed in leukemic blasts of adult patients and in early relapse childhood leukemia 
suggesting a correlation between the GRP78 DNA binding affinity and the anti-leukemic activity 
of the aminoacyl nucleolipid. We are currently investigating the molecular basis for the potent and 
selective anti-cancer activity of the aminoacyl nucleolipid.    
 
 
Figure 1.17. Cell death of human leukemia cell lines following treatment with 
aminoacylnucleolipid, 1.28, (10 µM) for 48 h. 
 
 
1.7. THESIS RESEARCH OBJECTIVES  
 
In an effort to exploit the cell death effects of D-(KLAKLAK)2, and improve its ‘drug-like’ 
properties, chemically robust and structurally pre-organized amphiphilic nucleolipids are proposed 
to enhance cell permeability and mitochondria localization in tumor cell types for potent and long-
lasting anti-cancer effects (Figure 1.18). These amphiphilic nucleolipids are inspired from our 
previous study on the so-called aminoacyl nucleolipid [40]. Building upon this work, the novel 
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nucleolipids described in this thesis are rationally designed to contain a reactive 5’-carboxy group 
for introduction within the pro-apoptotic D-(KLAKLAK)2 sequence by solid phase peptide 
synthesis. The nucleolipid is based on a thymidine nucleoside that provides a chemically resilient 
and structurally pre-organized scaffold, and long chain alkylamines that are proposed to facilitate 
cell penetration and mitochondria localization within tumor cell.  
 
 
 
 
 
 
 
Figure 1.18. Design and structure of the amphiphilic nucleolipids synthesized in this study. 
 
In this study, the design, synthesis, characterization, and cancer cell death activity of a new 
class of peptide nucleolipids is described. This thesis will present a new class of palmitamide and 
nucleolipid derived D-(KLAKLAK)2 bioconjugates in Chapter 2. A presentation of its synthesis, 
biophysical and anti-cancer activity is described and related to the native, peptide sequence. 
Chapter 3 will describe a diversity oriented synthesis approach for making chemically diverse 
nucleolipids that may be useful in exploring structure-function relationships of the bioconjugates 
and their cancer cell targets. This chapter will also highlight the potential of this methodology; in 
building libraries from libraries of nucleolipid derivatives that may be easily incorporated within 
other lead biologicals or in themselves present an element of anti-cancer activity. Finally, the D-
(KLAKAK)2-nucleolipid conjugates may also be functionalized with tumor homing vectors, for 
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selective and effective treatment of cancer cell types. The latter forms an important part of the 
precision medicine initiative currently in progress in our group for the rapid and selective diagnosis 
and treatment of cancer. These contributions to knowledge (Chapter 4) and supporting information 
(Appendix) will be presented as the final sections of this thesis.    
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CHAPTER 2. SYNTHESIS, CHARACTERIZATION AND ANTI-CANCER ACTIVITY 
OF A PEPTIDE-NUCLEOLIPID BIOCONJUGATE 
2.1 ABSTRACT 
 The nucleolipids form an interesting class of bioconjugates displaying desirable bio-
physical and biological properties for applications in cancer detection and therapy. They own the 
ability to self-assemble into amphiphilic higher-order nanostructures  which contributes to their 
biological relevance in medicinal chemistry. Therefore, nucleolipids have also been used in the 
delivery of hydrophobic drugs, biologicals and fluorescent probes for the detection and treatment 
of malignant cells. Structurally, the amphiphilic nucleolipids are composed of hydrophobic lipid 
appendages that are connected to a nucleoside core forming an amphiphile that may be further 
functionalized for medicinal chemistry applications. In spite of their utility, the nucleolipids 
remain limited by tedious total synthesis strategies, solubility issues in biological media and the 
susceptibility towards aggregation that may limit their biological function in live cells. In order to 
address these limitations, this chapter describes the synthesis, characterization and anti-cancer 
activity of a new class of amphiphilic peptide-nucleolipid bioconjugate. The approach began with 
the synthesis of a reactive carboxy-derived thymidine nucleolipid. The nucleolipid is based on a 
thymidine nucleoside that provides a chemically resilient and structurally pre-organized scaffold, 
and long chain alkylamines that are proposed to facilitate cell penetration and mitochondria 
localization for anti-cancer activity within tumor cells. Key to the synthesis strategy is a reductive 
amination procedure for installing the alkylamines onto the 3’-aldehyde derived thymidine 
building block. In this manner, a diversity oriented approach may be envisioned for the generation 
of functionally diverse nucleolipids. Deprotection and oxidation afforded the 5’-carboxy-derived 
nucleolipid which was then conjugated to the D-(KALAKLAK)2-AK sequence. This peptide 
sequence is known as the killer peptide due to its ability to disrupt mitochondria structure and 
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function ultimately leading to apoptosis. The nucleolipid is anticipated to function as a vector, 
facilitating the penetration of the D-(KALAKLAK)2-AK in tumors for potent anti-cancer activity. 
This chapter will further describe the outcome of a first representative example of a peptide-
nucleolipid bioconjugate.  
2.2 CHAPTER OBJECTIVES 
 This thesis chapter aims to describe the design, synthesis and characterization of a new 
class of peptide nucleolipid bioconjugates for anti-cancer applications. In order to accomplish 
these research objectives, a simple, reliable and reproducible synthesis strategy for making a 5’-
carboxy 3’-hexadecylamine thymidine nucleolipid has been developed. This synthesis strategy 
features a key reductive amination step that was used to install hexadecylamine onto the 3’-
aldehyde derived thymidine. This reaction afforded the desired nucleolipid in good yields and 
purities. Additionally, it may also be extended to other alkylamines for making libraries of 
functionally diverse nucleolipids for exploring structure-activity relationships with malignant 
cellular targets. Following deprotection and oxidation of the 5’-OH to the 5’-CO2H, the carboxy-
derived nucleolipid was characterized by a combination of chromatography and spectroscopy to 
ascertain identity and purity. The second objective is related to the solid phase peptide synthesis 
of the antimicrobial peptide D-(KLAKLAK)2. In spite of its antiseptic activity, the D-
(KLAKLAK)2 sequence lacks mammalian cell permeability and cytotoxicity. Many efforts have 
been developed to improve the cytotoxic activity of the D-(KLAKLAK)2 sequence in malignant 
mammalian cell types. Among the most commonly used methods is conjugation of the peptide 
with amphiphilic vectors that improve permeability across the mammalian cell membrane and 
promote localization at the mitochondria for cytotoxic activity. In the second objective, a solid 
phase synthesis approach has been developed for making an orthogonally protected D-
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(KLAKLAK)2-AK sequence. Liberation of the C-terminus amino group from the Lys side chain 
facilitated the development of a HCTU-based coupling reaction in between the peptide and 
carboxy derived nucleolipid to generate the peptide-nucleolipid bioconjugate. The desired peptide 
nucleolipid bioconjugate was then characterized by a combination of chromatography, 
spectroscopy and microscopy to fulfill the requirement of our third research objective, related to 
the characterization of the peptide-nucleolipid bioconjugate.  In collaboration with Suing Huang 
(Ph.D. student) in the laboratory of Dr. Uri Samuni (Department of Chemistry, Queen’s College) 
dynamic light scattering (DLS) and transmission electron microscopy (TEM) experiments were 
accomplished in order to validate the higher-order nanoparticle formulation of the bioconjugate. 
The final research objective in this study was aimed towards investigating the potential anti-cancer 
activity of the peptide nucleolipid bioconjugate. A screening assay was performed at the National 
Cancer Institute (NCI), in which a single dose treatment of the peptide nucleolipid bioconjugate 
was administered to 60 different cancer cell lines to determine inhibitory growth effects and 
cytotoxicity. Completion of these research objectives led to the identification of a lead peptide 
nucleolipid bioconjugate that may have anti-cancer utility in a selected panel of cancer cells lines. 
This thesis chapter will provide additional insights to the completion of the research objectives 
towards the synthesis, characterization and anti-cancer evaluation of a newly developed peptide-
nucleolipid bioconjugate.  
2.3 INTRODUCTION 
The so-called “killer” peptide sequence D-(KLAKLAK) 2 has been originally designed and 
developed as an antimicrobial agent [1]. This peptide sequence was found to maintain selective 
cytotoxic activity towards bacteria, but not in mammalian cell types. The chemical basis for its 
selectivity has been attributed to its poly(cationic) amphiphilic nature, which facilitates 
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translocation across the negatively charged bacterial cell membrane, but with limited permeability 
across the zwitterionic membrane of mammalian cell types [2]. Once internalized within cells, the 
positively charged D-(KLAKLAK)2 sequence has been found to associate to the surface of the 
mitochondria causing dissipation of the negatively charged mitochondrial membrane potential [3]. 
This depolarization resulted in a loss of mitochondrial structure integrity that caused membrane 
rupture and the release of mitochondrial contents into the cytoplasm. The release of the cell death 
effectors from the mitochondria, including cytochrome c, the second mitochondrial-derived 
activator of caspase (Smac/DIABLO) and the apoptosis-inducing factor (AIF) ultimately resulted 
in programmed cell death [4].  In an effort to exploit the cell death effects of D-(KLAKLAK)2, 
modifications to the primary sequence [5] and conjugation with cell penetrating, targeting peptides 
and proteins [6-14] have resulted in improved cell translocation and cytotoxic activity within 
malignant mammalian cell types, such as in human cancers. In spite of their utility, effective 
methods for the safe and long-lasting administration of peptide-based therapeutics are still in 
widespread demand. Limitations which include poor peptide cell permeability, minimal exposure 
and resident time at the target tumor site for activity have impeded the translation of bio-active 
peptides such as the D-(KLAKLAK)2 sequence from pre-clinical to clinical use. In an effort to 
mitigate these limitations and improve the ‘drug-like’ properties of the pro-apoptotic D-
(KLAKLAK)2 sequence, an amphiphilic nucleolipid is proposed to enhance cell permeability and 
mitochondria localization in tumors, resulting in potent and long-lasting anti-cancer effects.  
The nucleolipids represent an interesting class of bioconjugates with the ability to form 
stable, higher-ordered nanostructure formulations for potential applications in medicinal chemistry 
[15, 16]. For example, they have been shown to form complexes with short-interfering RNA 
(siRNA), facilitating siRNA transfection across cell membranes and leading to the down-
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regulation of mRNA expression in cancer cells [17-19]. Moreover, the synthesis, GRP78 oncogene 
binding and selective anti-cancer activity of a novel aminoacyl nucleolipid bioconjugate within 
the SR human leukemia cancer cell line has been described [20]. Thus, the nucleolipids have 
effectively served as robust delivery vehicles for biologicals and as potent cytotoxic agents for 
enhancing the cell death responses in cancer. In this study, a thymidine-derived nucleolipid is 
rationally designed to contain a reactive carboxy group for coupling with the pro-apoptotic D-
(KLAKLAK)2 sequence. This strategy will enable the introduction of functionally diverse 
nucleolipids within the D-(KLAKLAK)2 sequence in order to improve structure-activity 
relationships in malignant cancer cell types. 
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2.3.1 SYNTHESIS, CHARACTERIZATION AND ANTI-CANCER ACTIVITY OF A 
PEPTIDE NUCLEOLIPID BIOCONJUGATE 
Niki Ranaa, Suiying Huangb, Pradeepkumar Patela, Uri Samunib, and David Sabatinoa,* 
aDepartment of Chemistry and Biochemistry, Seton Hall University, 400 South Orange Avenue, South Orange, New 
Jersey  07079, United States 
bDepartment of Chemistry, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing , New York  
11367, United States and the Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City 
University of New York, New York, NY 10016 
 
 
Figure 2.1. Graphical abstract of the peptide-nucleolipid bioconjugate developed in this study. 
Figure adapted from Rana, N., Huang, S.; Patel, P.; Samuni, U.; Sabatino, D. Bioorg. Med. 
Chem. Lett., 2016, 26, 3567–3571. 
 
2.3.2. RESULTS AND DISCUSSION 
2.3.3. SYNTHESIS OF A 5’-CARBOXY 3’-HEXADECYLAMINE THYMIDINE 
DERIVED NUCLEOLIPID 
    The synthesis of nucleolipid 2.6 (Scheme 2.1) was initiated by the regioselective 
attachment of the allyl group at the 3’-hydroxyl of commercially available 5’-O-(4-
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dimethoxytrityl) DMT- thymidine, 2.1. The allylation reaction proceeded smoothly with sodium 
hydride (NaH) as base, and allyl bromide as alkylating reagent resulting in 87% yield of the mono-
allylated nucleoside, 2.2, and without any observable allylation on thymine.  The allyl group in 2.2 
was then oxidized to the aldehyde, 2.3, and isolated in 84% yields following silica gel column 
chromatography. The reactive 3’-aldehyde was subsequently condensed with hexadecylamine and 
reduced using sodium cyanoborohydride to yield the alkylamine–derived thymidine, 2.4. This two-
step one-pot reductive amination reaction favored the formation of the desired intermediate, 2.4, 
in 43% yields. In this reaction, the conversion of the imine to secondary amine was closely 
monitored by 1H NMR which confirmed the disappearance of the iminium proton (δ: 6.85 ppm) 
upon complete reduction of the Schiff base. Following quantitative removal of the 5’-DMT group 
using trichloroacetic acid (TCA), a TEMPO-mediated oxidation reaction converted the 5’-hydroxy 
to the carboxylic acid, 2.6, in 50% yield. Each reaction intermediate and the final product, 2.6, 
were characterized by NMR, IR spectroscopy and by MS to confirm purities and identities.  
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Scheme 2.1. Synthesis of 5’-carboxy-derived thymidine nucleolipid, 2.6 
Conditions: (a) allyl bromide, NaH, THF, sonication, r.t., 3hr, 87%, (b) 4% OsO4 in t-BuOH, 
NMO, Na2S2O4, NaIO4, acetone:phosphate buffer (3:1 v/v), 84%, (c) i) 1-hexadecylamine, THF, 
r.t., 20 min, ii) NaBH3CN, THF, r.t., 4hr, 43% (d) 3% TCA:DCM, r.t., 4h, >99%, (e) i) TEMPO, 
BAIB, DCM, r.t., 2h, ii) MeCN:Water r.t., 24 hr, 50%.  
 
2.3.4 DESIGN AND SYNTHEIS OF D-(KLAKLAK)2-AK PEPTIDE SEQUENCE AND ITS 
RELATED ANALOGUES.  
The thymidine derived nucleolipid was rationally designed and synthesized to contain a 
reactive carboxy group for coupling with the pro-apoptotic D-(KLAKLAK)2 sequence, to afford 
the desired peptide-nucleolipid bioconjugate (Figure 2.1). The thymidine nucleoside provides a 
chemically resilient and structurally pre-organized scaffold [21] while the long chain alkylamine 
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is anticipated to enhance cell permeability and mitochondria localization of the D-(KLAKLAK)2-
AK sequence for potent anti-cancer activity. Moreover, the native peptide, D-(KLAKLAK)2-AK, 
and the palmitamide-derived D-(KLAKLAK)2-AK sequences were also synthesized and used as 
controls to evaluate the influence of the nucleolipid on the biophysical, structural and biological 
properties of the D-(KLAKLAK)2-AK sequence (Figure 2.2A). 
 
Figure 2.2 A. Peptide structures. The D-(KLAKLAK)2-AK peptide scaffold with R1(red) = H or 
FITC, R2(blue) = H, Nucleolipid or Palmitamide. R1, R2 = H, 2, R1 = FITC, R2 = H, 5, R1 = H, R2 
= Palmitamide, 3, R1 = H, R2 = Nucleolipid, 4, R1 = FITC, R2 = Palmitamide, 6, R1 = FITC, R2 = 
Nucleolipid, 7. All amino acids are in their D-configuration. 
 
The synthesis of the D-(KLAKLAK)2-AK sequence, 2.7, was accomplished by 
conventional Fmoc-solid phase peptide synthesis on a Rink amide hydrophilic poly(ethylene 
glycol) resin (Nova PEG, 0.47 mmol/g) [22]. At the N-terminus of the peptide sequence an 
aminohexanoic acid (AHx) linker was attached for the incorporation of fluorescein isothiocyanante 
(FITC) [23]. Following cleavage and deprotection, the FITC-labeled peptide sequence, 2.10, was 
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isolated by RP-HPLC for characterization studies. At the C-terminus, an orthogonally protected 
Lys(Dde) residue was selectively deprotected on solid-phase using hydroxylamine hydrochloride 
buffered with imidazole. These mild conditions have been shown to cleave the Dde group without 
concomitant Fmoc-deprotection that has been shown to occur when hydrazine is used as Dde 
deblocking reagent [24]. Bioconjugation was first attempted by coupling palmitic acid at the C-
terminus of the partially deprotected peptide sequence, 2.14, bound to the solid support (Scheme 
2.2). Optimized conditions for peptide coupling reactions using HCTU as coupling reagent and 
NMM as base were adopted for making the desired bioconjugates on solid support. 
The palmitamide-derived D-(KLAKLAK)2-AK sequence was Fmoc-deprotected and 
either coupled with FITC at the N-terminus, followed by cleavage and deprotection from solid-
phase, or was directly cleaved and deprotected for LCMS analysis and purification. The 
palmitamide-derived D-(KLAKLAK)2-AK sequence, 2.9, and the FITC-labeled sequence, 2.12,  
Scheme 2.2. Synthesis of FITC and non-FITC labeled D-(KLAKLAK)2-AK conjugated with 
nucleolipid 2.6 or with palmitic acid. 
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were isolated by RP-HPLC and their identities were confirmed by MS. These coupling conditions 
were adopted for the synthesis of the nucleolipid-derived D-(KLAKLAK)2-AK sequence, which 
was also produced respectively 2.8 and 2.11, without and with the FITC label. In either cases, the 
peptide bioconjugates were isolated in sufficient yields (10-33%) and purities (≥96%) for the 
structure-activity relationship studies. 
 
2.4 CHARACTERIZATION OF D-(KLAKLAK)2-AK AND ITS RELATED 
ANALOGUES. 
The peptide bioconjugates were anticipated to display greater hydrophobicity relative to 
the native D-(KLAKLAK)2-AK sequence. The enhanced hydrophobic character of cell-
penetrating peptides has been shown to improve their membrane translocation, presumably due to 
the favorable non-polar interactions in between the hydrophobic side-chain residues of the peptides 
and the long-chain alkyl groups found within the lipid bilayer [25]. Comparison of the retention 
times on RP-HPLC (Figure 2.2. B) for the native, D-(KLAKLAK)2-AK sequence, 2.7, RT = 6.5 
min, with the palmitamide-derived D-(KLAKLAK)2-AK, 2.9, RT = 17.6 min, and the nucleolipid-
derived D-(KLAKLAK)2-AK, 2.8, RT = 11.3 min, confirmed that the palmitamide, followed by 
the nucleolipid produced the greatest hydrophobic effects onto the native D-(KLAKLAK)2-AK 
sequence.  
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Figure 2.2 B.  RP-HPLC comparison study of the native, nucleolipid and palmitamide-derived D-
(KLAKLAK)2-AK biooconjugates. Column: Waters Symmetry Shield C18, 5µm, 4.6x150 mm 
Mobile Phase: 2-80% MeCN:H2O_0.1%FA PDA detection at: 220 nm. 
 
The complete LC/MS characterization data for the peptides synthesized in this study is 
provided in Table 2.1. Of note, pure peptides were isolated following RP HPLC purification in 
purities>95%. Peptide purities were also confirmed in two different eluent systems which indicated 
single isolated peptide peaks at their characteristic retention times. The molecular weight identities 
of the peptides were confirmed as their mass:charge, in which multiple charge states, presumably 
due to the positively charged Lys ammonium groups were detected on ESI MS. Nonetheless, the 
peptides were isolated and characterized by LC/MS in sufficient quantities and purities for 
investigating their biophysical, structural and biological properties. 
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Table 2.1 Characterization data of peptides 
Entry Sequence a
Crude 
Purity 
(%) 
b
Isolated 
Purity (%) 
hIsolated 
Yield(%/mg) 
iM.W. 
(g/mol) 
Expt(Theoratical) 
jZ kRT 
(min) 
lRT 
(min) 
1 D-(KLAKLAKKLAKLAK) 93 c>99 56/(21.4) 508.5(507.0) 3 f7.5 c6.9 
2 AHx-D-
(KLAKLAKKLAKLAK)-AK 
68 d>99 64/(29) 459.7(459.0) 4 f6.5 d4.2 
3 AHx-D-
(KLAKLAKKLAKLAK)-AK-
C
16
H
31
O (Palmitamide) 
49 e>99 33/(8.3) 518.5(519.3) 4 g17.6 e13.8 
4 AHx-D-
(KLAKLAKKLAKLAK)-AK-
C
28
H
48
N
3
O
5 
(Nucleolipid) 
42 f96 10/(2.1) 468.8(468.4) 5 f11.3 d6.3 
5 FITC-AHx-D-
(KLAKLAKKLAKLAK)-AK 
93 f>99 20/(4.0) 
  
445.8(445.0) 5 f10.5 d6.0 
6 FITC-AHx-D-
(KLAKLAKKLAKLAK)-AK-
C
16
H
31
O (Palmitamide) 
93 g>99 5/(2.0) 
  
  
  
493.6(492.6)  5 g15.4 e5.7 
7 FITC-AHx-D-
(KLAKLAKKLAKLAK)-AK-
C
28
H
48
N
3
O
5 
(Nucleolipid) 
82 g96 30/(4.8) 546.9(546.2) 
  
5 g10.5 e10.5 
 
aCrude purities by RP-HPLC at 220 nm. bIsolated purities by RP-HPLC at 220 nm using c2-83% 
MeCN/H2O with 0.1% TFA over 18 min, 
d2-80% MeCN/ H2O with 0.1% FA over 17 min, 
e20-80 
MeCN/ H2O with 0.1% FA over 17 min, 
f2-80% MeOH/ H2O with 0.1% FA over 17 min, 
g20-80 
MeOH/H2O with 0.1% FA over 17 min. 
hIsolated yields based on the resin loading. iObserved 
mass (expected mass) as [M+H]+/Z as detected by LCMS. jCharged state of the peptides as 
detected by LCMS in positive mode. kRetention times using methanol/water. lRetention times 
using acetonitrile/water. ( c2-83% MeCN/H2O with 0.1% TFA over 18 min, 
d2-80% MeCN/ H2O 
with 0.1% FA over 17 min, e20-80 MeCN/ H2O with 0.1% FA over 17 min,
 f2-80% MeOH/ H2O 
with 0.1% FA over 17 min, g20-80 MeOH/H2O with 0.1% FA over 17 min.) 
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The hydrophobicity of the peptide bioconjugates was also confirmed by the DLS zeta 
potential measurements and the logP values evaluating the octanol:water partition coefficients of 
the FITC-labeled peptides at 490 nm (Table 2.2). Furthermore, UV-Vis spectroscopy also 
confirmed the characteristic absorption bands of the peptide bonds (λmax ~ 220 nm) and the thymine 
base (λmax ~ 260 nm) corresponding to the nucleolipid-derived D-(KLAKLAK)2-AK, 2.8, (Figure 
2.2C).  
 
Figure 2.2C. UV/Vis spectroscopy (190–300 nm) of the peptides. Inset shows the nucleolipid-
derived D-(KLAKLAK)2-AK, absorbance at 260 nm. 
 
CD spectroscopy was then used to evaluate the secondary structures (if any) of the peptides 
in H2O:TFE. The combination of H2O:TFE has been especially useful in mimicking the 
amphiphilic lipid bilayer microenvironment that has served to stabilize peptide secondary 
structures in solution [26]. In this study, the native, D-(KLAKLAK)2-AK sequence, 2.7, displayed 
a stable, α-helical secondary structure (65% helicity), while the palmitamide-derived D-
(KLAKLAK)2-AK, 2.9, displayed enhanced helicity (76%) and the nucleolipid-derived D-
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(KLAKLAK)2-AK 2.8, demonstrated a less stable (42%) α-helical secondary structure (Figure 
2.2D and Table 2.2).  
 
Figure 2.2D. CD spectra of peptides at 12.5 µM in H2O: TFE (50:50, v/v)   
 
Many amphiphilic cell-penetrating peptides adopt α-helical secondary structures. In certain 
cases, this peptide motif functions as a recognition site with other membrane spanning proteins 
(such as the pore proteins) and facilitates cellular translocation activity [27]. The amphiphilic α-
helical peptides, 2.7, 2.9 and 2.8, were subsequently analyzed by DLS and TEM to determine ionic 
charge, size, shape and particle distributions (Figure 2.3). The DLS data (Table 2.2 confirmed 
positively charged peptide ionic structures according to the zeta-potential measurements obtained 
in H2O.  The size distributions (60 – 300 nm) detected by DLS and TEM were found to be 
comparable and indicated a single, major population of nanoparticles for each formulation (Figure 
2.3). 
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Table 2.2. Structural and biophysical properties of the peptide sequences. 
Sequencea % 
Helicityb 
#of 
Helical 
residuesc 
Hydrophobicityd 
 
Size(nm) Zeta 
potential
g(mV) 
   %AcN 
elution 
cLogP DLS e TEM f  
AHx-D-(KLAKLAK)2-AK 65 9 17 n.a. 270±80 70-150 30 
AHx-D-(KLAKLAK)2-AK-R
1 76 11 32 n.a. 190±70 70-150 7 
AHx-D-(KLAKLAK)2-AK-R
2 42 6 25 n.a. 310±90 60-120 6 
FITC-AHx-D-(KLAKLAK2-AK n.a. n.a. 24 -1.44±0.40 n.a. n.a. n.a. 
FITC-AHx-D-(KLAKLAK)2 AK-R
1 n.a. n.a. 22 -0.36±0.02 n.a. n.a. n.a. 
FITC-AHx-D-(KLAKLAK)2)-R
2 n.a. n.a. 42 -0.41±0.05 n.a. n.a. n.a. 
 
Structure and comparison of hydrophobicity and helicity of the D-(KLAKLAK)2-AK analogues. 
aSequence compositions D-(KLAKLAK)2-AK with R
1 = palmitamide, R2 = nucleolipid, and FITC, 
b% Helicity calculated from observed ellipticity [Ɵ] at 222 nm using CD spectroscopy, c# of helical 
residues calculated from the % helicity determined using CD spectroscopy, dHydrophobicity 
measured as % acetonitrile elution from the RP-HPLC C18 column, LogP values (average and 
standard deviation of three independently conducted experiments) calculated from partitioning 
between 1-octanol and 10mM Tris pH 7.4 measured for the FITC-labeled (KLAKLAK)2 peptides 
using UV-Vis spectroscopy at 492 nm, e,fReported size of the peptide-based nanoparticle 
formulations based on DLS and TEM measurements.  gZeta potential measurements for the peptide 
samples obtained in water at 25ºC. 
 
For example, the native D-(KLAKLAK)2-AK sequence, 2.7, displayed, uniform, square 
shaped particles ranging in sizes from 70 – 270 nm. The palmitamide-peptide bioconjugate, 2.9, 
produced smaller, spherical-shaped particle sizes (70 – 190 nm), while the nucleolipid-peptide 
bioconjugate 2.8, demonstrated the largest particle size formulation (60 – 310 nm). Taken 
altogether, these results suggests that the peptides may exhibit favorable biophysical and structural 
properties for their applications in molecular cancer cell biology.  Considering the self-assembly 
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and nanoparticle formulation of similar amphiphilic D-(KLAKLAK)2 sequences have led to 
significant anti-cancer effects [28] the cancer cell line toxicities of the peptides were subsequently 
evaluated. 
 
Figure 2.3. TEM images and DLS particle diameter size distributions of A) The native D-
(KLAKLAK)2-AK sequence, 2.7, B) the palmitamide-derived D-(KLAKLAK)2-AK sequence, 
2.9, and C) the nucleolipid-derived D-(KLAKLAK)2-AK sequence, 2.8. 
 
2.5 BIOLOGICAL EVALUATION OF THE D-(KLAKLAK)2-AK SEQUENCE AND ITS 
RELATED ANALOGUES 
A lethality assay was performed against a panel of 60 cancer cell lines at National Cancer 
Institute (NCI) [29]. A single dose screen was performed with the native, D-(KLAKLAK)2-AK 
sequence, 2.7, (10 M), the palmitamide-derived D-(KLAKLAK)2-AK sequence, 2.9, (7.25 M), 
and the nucleolipid-derived D-(KLAKLAK)2-AK sequence, 2.8, (2.13 M). The cell growth data 
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(Figures 2.4-2.6) indicated that the peptides were found to be most active towards a panel of non-
small cell lung carcinoma (NSCLC). Interestingly, the palmitamide and nucleolipid-derived D-
(KLAKLAK)2-AK sequences, 2.9 and 2.8, showed the highest toxicity (~30%) within the A549 
NSCLC cell line, resulting in a 1.5-fold enhancement relative to the native D-(KLAKLAK)2-AK 
sequence, 2.7, (~20%) (Table 2.3).  
 
Table 2.3. NCI-60 cancer cell line screen lethality (% cell death) data for a selection of human 
Non-Small Cell Lung Cancer cell lines. 
Lethality (% cell death) in NSCLC 
Sequence A549 NCI-H226 NCI-H522 
Native, 2.7 19 1 14 
Palmitamide, 2.9 32 0 16 
Nucleolipid, 2.10 31 4 11 
 
These results correlate nicely with the recently reported anti-cancer effects of the 
amphiphilic D-(KLAKLAK)2-phospholipid liposome formulation which enhanced the 
cytotoxicity of the killer peptide sequence within the A549 lung cancer cells and within the drug-
resistant lung cancer A549/Taxol cell line [30]. Thus, the amphiphilic palmitamide or nucleolipid-
derived D-(KLAKLAK)2-AK sequences represents an interesting class of bioconjugates that have 
served to potentiate the cancer cell death response of the native D-(KLAKLAK)2-AK within the 
A549 lung cancer cell line. Furthermore, the cytotoxic selectivity for cancer cell lines over normal 
tissues for bioconjugates 2.8 and 2.9 is unanticipated but may be introduced by the incorporation 
of cancer cell targeting ligands [6,7,9,12-14].  
57 
 
  
 Figure 2.4. NCI 60 cancer cell line screen for determining growth inhibition and cytotoxic activity 
for a single dose (2.13 M) treatment of nucleolipid-derived D-(KLAKLAK)2-AK, 2.8. 
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Figure 2.5. NCI 60 cancer cell line screen for determining growth inhibition and cytotoxic activity 
for a single dose (7.25 M) treatment of palmitamide-derived D-(KLAKLAK)2-AK, 2.9. 
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Figure 2.6. NCI 60 cancer cell line screen for determining growth inhibition and cytotoxic activity 
for a single dose (10 M) treatment of D-(KLAKLAK)2-AK, 2.7 
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2.6 CONCLUSIONS  
In conclusion, the synthesis, characterization and anti-cancer activity of a new class of 
killer peptide bioconjugates are reported in this chapter. The peptide bioconjugates were found to 
be more hydrophobic relative to the native sequence. Moreover, the peptide bioconjugates 
displayed α-helical structures and cationic nanoparticle formulations that were contributive 
towards their anti-cancer activities. Within a NCI-60 cancer cell line screen, the peptide 
bioconjugates displayed enhanced cell death activity relative to the native sequence within the 
human A549 lung cancer cell line. These results validates the anti-cancer utility of the new 
amphiphilic peptide bioconjugates and paves the way for a cancer cell biology study that may 
ultimately unveil their mechanism of action. Moreover, the development of a key reductive 
amination procedure for making nucleolipids provides an opportunity for the generation of a 
diversity oriented synthesis approach. The latter is envisioned for making a library of functionally 
diverse nucleolipids for their incorporation into a lead, such as the D-(KLAKAK)2 sequence, and 
for improving its structure-function properties in cancer cell types. Moreover, the peptide 
nucleolipid bioconjugate may also be functionalized with cancer-targeting peptide sequences for 
the development of a selective anti-cancer approach. The latter is of current research interest and 
some preliminary work detailing their development is presented in Chapter 3 of this thesis.    
 
2.7. EXPERIMENTAL SECTION  
General Methods: 
 All non-aqueous reactions were performed under inert atmosphere (nitrogen) unless 
otherwise specified. All glassware was cleaned and stored in a pre-heated oven (160 oC) for drying 
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and cooled in a dessicator prior to use. Anhydrous solvents and reagents were purchased from 
Aldrich (St. Louis, MO) and used as received. Analytical thin-layer chromatography (TLC) was 
performed on aluminum-backed silica gel plates (Merck 60 F254). TLCs were visualized under 
UV shadowing (260 nm) or staining (10% H2SO4/MeOH). Compound purification using silica gel 
chromatography was performed on a 230-400 mesh silica (Sorbent Technologies). Melting points 
were obtained on a Thermo Melt apparatus. Specific rotations measurements were recorded on a 
DigiPol 781 Automatic Polarimetry (Rudolph Instruments, Fairfield, NJ, USA) and collected as 
an average of five measurements per compound. Data are reported as follows: [α]λ temp, 
concentration (c in g/100 mL), in Acetone, MeOH, DCM or CHCl3.  Molecular weights were 
measured as direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ion-
source in positive mode using 50/50 v/v MeOH/H2O at a flow-rate of 1 mL/min. Infrared (IR) 
spectra were obtained on a Nicolet 4700 FT-IR (ThermoElectron Co.) coupled with OMNIC 
software (driver version: 7.1). The compounds were deposited on a KBr plate with the cast film 
technique and the data was collected as an average of 3 scans in wavenumbers (cm-1). Nuclear 
magnetic resonance spectra (1H, 13C, COSY NMR) were recorded on an Varian Inova NMR 
AS500 spectrophotometer. The NMR spectra were obtained at ambient temperature using an 
indirect pulse-field gradient (ID-PFG) probe. The obtained data was processed using VNMRJ 
software (version 2.2). The 1H and 13C assignments were based on gCOSY and gHMQC NMR 
correlation experiments.  
Synthesis:  
3’-O-(allyl)-5’-O-(dimethoxytrityl) thymidine (2.2): To a suspension of 60% NaH (220 mg, 9.19 
mmol) in anhydrous THF (20 mL) under argon at 0 °C was added 5’-O (dimethoxytrityl) thymidine 
(2 g, 3.67 mmol). After sonication for 20 min, allyl bromide (792 μL, 9.17 mmol) was added and 
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the reaction mixture was stirred at r.t. for 3 h. The mixture was poured into saturated NaHCO3 (40 
mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were then washed with 
brine (30 mL), dried over MgSO4, filtered and concentrated. Purification by flash column 
chromatography (EtOAc–petroleum ether, 1:1 v/v, 1% Et3N) afforded 3’-O-(allyl)-5’-O-
(dimethoxytrityl)thymidine as a white solid; yield: 1.65 g (87 %); m.p. 83 °C. [𝛼]589
23 :  +15.29 (c 
0.01, Acetone). Rf = 0.44 (EtOAc–petroleum ether, 7:3 v/v). IR (KBr) υmax (cm-1) = 3182.1, 
3059.1, 2929.9, 2836.8, 1693.4, 1607.7, 1582.3, 1508.9, 1464.5, 1364, 1273.5, 1251.1, 1177.1, 
1105.4, 1063.1, 1033.5, 915.8, 829.1, 791.1, 755.8, 727.0, 702.1.1H NMR (500 MHz, acetone-d6): 
δ = 1.52 (s, 3H), 2.42 (m, 2H), 3.43 (m, 2H), 3.82 (s, 6H), 4.07 (m, 2H), 4.10 (d, J  = 3.0 Hz, 1H), 
4.40 (t, J  = 3.0 Hz, 1H), 5.17 (dd, J  = 1.5, 10.5 Hz, 1H), 5.29 (dd, J = 1.5, 17.25 Hz,  1H), 5.93 
(m, 1H), 6.33 (dd, J = 6.0, 8.0 Hz, 1H), 6.94 (d, J  = 8.5 Hz, 4H), 7.28 (t, J  = 7.5 Hz, 1H), 7.35–
7.41 (m, 6H), 7.52 (d, J = 7.0 Hz, 2H), 7.64 (d, J  = 1.0, 1H). 10.03 (bs, 1H). 13C NMR (126 MHz, 
acetone-d6): δ = 11.34, 37.36, 54.69, 63.97, 69.76, 79.04, 83.79, 84.49, 86.68, 110.2, 113.2, 116.1, 
126.9, 127.9, 128.2, 130.1, 135.0, 135.5, 135.7, 135.8, 145.0, 150.4, 151.7, 158.9, 163.4, 179.2. 
ESI MS (m/z) calculated for C34H36N2O7  [M+Na], 607.2; found 607.2. 
 
3’-O-(formylmethyl)-5’-O-(dimethoxytrityl) thymidine (2.3): To a solution of 2.2 (1.63 g, 2.79 
mmol) in a mixture of acetone–H2O (12 mL, 3:1 v/v) was added NMO (0.65 g, 5.58 mmol) and a 
solution of 2.5% OsO4 in t-BuOH (1.8 mL). The mixture was stirred at r.t. for 2 h, then treated 
with Na2S2O5 (0.98 g, 5.15 mmol) and stirred for 30 min. The reaction mixture was then treated 
with H2O (50 mL) and the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined 
organic layers were washed with brine (100 mL), dried over MgSO4, filtered and concentrated. 
The residue was dissolved in a mixture of acetone phosphate buffer pH 7 (22 mL, 3:1 v/v), and 
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NaIO4 (1.50 g, 7.02 mmol) was added. The mixture was stirred at r.t. for 2 h, and then filtered, and 
the precipitate was washed with EtOAc (50 mL). The separated aqueous layer was extracted with 
EtOAc (2 × 50 mL) and then the combined organic layers were washed with brine (100 mL), dried 
over MgSO4, filtered and concentrated. The crude product 3’-O-(formylmethyl)-5’-O-
(dimethoxytrityl) thymidine (solid; 1.50 g, 84%) was used directly as recovered. m.p. 123 °C. 
[𝛼]589
23 : +3.61 (c 0.80, acetone). Rf = 0.55 (CH2Cl2–MeOH, 9:1). IR (KBr) υmax (cm-1) = 3307, 
3066.8, 3007.3, 2953.4, 2929.6, 2856.5, 1736.7, 1698.6, 1660.3, 1610.8, 1557.2, 1509.6, 1485.4, 
1445.8, 1382.6, 1300.8, 1253.5, 1217.4, 1176.1, 1109.9, 1072, 1034.8, 1002.6, 968.5, 936.6, 890.7, 
863.6, 755.8, 704.6, 667.9 1H NMR (500 MHz, DMSO-d6): δ = 1.44 (s, 3H), 2.29-2.38 (m, 2H),  
3.36 (dd, J  = 3.0, 10.8 Hz, 1H), 3.45 (dd, J  = 3.0, 10.8 Hz, 1H), 3.79 (s, 6 H), 4.06–4.10 (m, 2H), 
4.18 (d, J  =  2.5 Hz, 1H),  4.24 (d, J  = 6.0 Hz,  1H), 6.19 (t, J  = 2.0 Hz, 1H), 6.91 (dd, J  = 1.0, 
9.30 Hz, 4H), 7.23–7.28 (m, 7H), 7.40 (d, J  = 7.0 Hz, 1H), 7.52 (d, J  = 1.5 Hz, 1H), 9.55 (s, 1H), 
11.4 (s, 1H). 13C NMR (126 .9 MHz, DMSO-d6): δ = 12.1, 14.5, 14.6, 21.2, 36.8, 39.4, 39.6, 39.7, 
40.0, 40.1, 40.2, 40.4, 55.5, 60.2, 64.2, 74.7, 80.4, 83.3, 84.1, 84.2, 87.0, 110.2, 114.0, 113.7, 
127.2, 128.1, 128.4, 130.1, 130.2, 135.6, 135.8, 136.0, 145.1, 151.0.  ESI MS (m/z) calculated for 
C33H34N2O8 [M+H], 586.2; found 586.2. 
 
3’-O-(hexadecylaminoethyl)-5’-O-(dimethoxytrityl) thymidine (2.4): The starting material 2.3 
(250 mg, 0.04 µmol) and 1-hexadecylamine (194 mg, 0.036 µmol) were dissolved in 3 mL of dry 
THF. The reaction was stirred for 20 min at room temperature and sodium cyanoborohydride (80 
mg, 0.05 µmol, 1.5 equiv) was added to reaction mixture and stirred for 4 hrs. The reaction was 
then concentrated in vacuum and purified by flash column chromatography using 
EtOAc:Petroleum ether (6:4 v/v) to yield a white foamy product 2.4 in 43% yield. m.p. 70 °C. 
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[𝛼]589
23 : +9.11 (c 0.01, DCM). Rf = 0.50 (EtOAc–petroleum ether, 6:4 v/v). IR (KBr) υmax (cm-1) = 
3168.8, 3060.7, 2924.4, 2853.1, 2421.0, 1843.9, 1791.9, 1771.9, 1761.2, 1750.2, 1733.4, 1691.9, 
1678.5, 1635.7, 1607.4, 1583.0, 1550.2, 1540.5, 1510.6, 1467.2, 1418.9, 1363.3, 1295.9, 1275.0, 
1251.7, 1177.1, 1100.7, 1035.5, 964.0, 902.1, 829.4, 790.9, 754.8, 727.2, 702.0, 585.3, 492.7, 
418.6. 1H NMR (499.84 MHz, CD2Cl2): δ = 0.91 (t, J  = 7.0 Hz, 3H), 1.30 (t, J  = 10.5 Hz, 28H) , 
1.50 (d, J  = 12.0 Hz, 3H), 1.57 (s, 1H), 2.23 (m, 1H), 2.46 (t, J  = 6.0 Hz, 1H), 2.81 (d, J  = 8.0 
Hz, 1H), 3.00 (m,  2H), 3.33 (m, 1H), 3.44 (d, J = 11 Hz, 1H), 3.64 (m, 1H), 3.75–3.83 (m, 8H), 
4.11 (dd, J  = 2, 14.5 Hz, 1H), 4.21 (d, J  = 5.0 Hz, 1H), 6.29 (m, 1H), 6.85 (m, 4H), 7.24-7.33 (m, 
7H), 7.41 (d, J  = 10.0 Hz, 2H), 7.46 (s, 1H). 13C NMR (125.6 MHz, CD2Cl2): δ = 22.6, 25.7, 25.8, 
26.5, 29.1, 29.3, 29.4, 29.5, 29.6, 31.9, 53.0, 53.1, 53.4, 53.6, 53.8, 55.2, 55.3, 111.1, 113.2, 128.0, 
130.0, 131.0, 135.3, 135.4, 158.9. ESI MS (m/z) calculated for C49H69N3O7  [M+H], 812.5; found 
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3’-O-(hexadecylaminoethyl)-thymidine (2.5): A solution of 3% TCA in DCM (10 mL) was 
added dropwise at room temperature to 2.4 (100 mg, 0.123 mmol). The reaction was continued for 
3 hr, the mixture was concentrated and loaded directly onto a column chromatography for 
purification. The crude was purified (EtOAc:Petroleum ether, 3:2 v/v) to obtain >99% of a white 
foamy product. m.p. 79 °C.  [𝛼]589
23  -3.088 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 
6:4). IR (KBr) υmax (cm-1) = 3632.9, 3572.0, 3410.1, 2923.6, 2853.2, 2424.5, 1733.4, 1709.2, 
1703.0, 1692.0, 1678.0, 1665.7, 1659.0, 1642.3, 1468.4, 1378.1, 1276.8, 1098.1, 821.3, 775.2, 
675.1. 1H NMR (499.9 MHz, DMSO-d6): δ = 0.87 (t, J  = 6.75 Hz, 2H), 1.24 (s, 19H),  1.60 (bs, 
1H), 1.79 (s, 3H), 2.14 (d, J  = 6.5 Hz, 1H), 2.22-2.25 (m, 1H), 2.52 (s, 2H), 2.69 (d, J  = 5.0 Hz, 
1H), 2.76 (t, J  =  5.25 Hz, 1H), 2.90 (t, J  = 4.25 Hz, 2H), 3.60 (s, 1H), 3.70 (s, 1H), 4.0 (m, 1H), 
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4.10 (d, J = 3.0 Hz, 1H), 6.51 (bs, 1H),  6.14-6.17 (m, 1H), 7.71 (s, 1H), 11.2 (s, 1H). 13C NMR 
(126.9 MHz, DMSO-d6): δ = 12.7, 14.3, 14.4, 22.5, 24.9, 26.8, 29.0, 29.1, 36.6, 52.0, 53.2, 62.0, 
64.4, 68.0, 80.2, 80.2, 80.3, 84.2, 84.3, 84.8, 84.9, 85.0, 110.0, 136.3, 136.4, 151.0, 164.1, 165.2. 
ESI MS (m/z) calculated for C28H51N3O5  [M-H], 509.7; found 510.5. 
 
3’-O-(hexadecylaminoethyl)-5’-carboxy-thymidine (2.6): To a solution of 2.5 (124 mg, 0.258 
mmol) in CH2Cl2 (1.3 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TEMPO) 
(9 mg, 0.06 mmol), and iodobenzene diacetate (BAIB) (184 mg, 0.570 mmol) at room temperature. 
After the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 140 L) was added to the 
reaction mixture and stirred for 24 h. After evaporation of the solvent, the residue was purified by 
flash chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as white powder in 
50% yield. [𝛼]589
23  (c 0.01, DCM), Rf = 0.20 (CHCl3: MeOH 9:1 v/v). 
1H NMR (499.8 MHz, 
DMSO): δ= 1.14 (t, J  = 6.75 Hz, 3H), 1.56 (t, J  = 13.2 Hz, 30H), 2.79-2.80 (m, 7H), 3.28-3.37 
(m, 1H), 3.6 (bs, 1H), 3.98-4.05 (m, 2H), 4.44-4.45 (m, 1H), 4.51 (d, J  = 1.5 Hz, 1H), 6.43-6.46 
(m, 1H), 9.37 (s, 1H), 11.46 (bs, 1H). 13C NMR (125.69 MHz, DMSO-d6): δ= 13.0, 14.3, 22.5, 
26.2, 27.0, 29.1, 29.5, 31.7, 39.5, 39.6, 40.0, 40.02, 40.1, 40.2, 40.3, 40.5, 83.2, 84.4, 86.0, 109.0, 
139.0, 151.0, 164.4, 173.4. ESI MS (m/z) calculated for C28H49N3O6 [M-H], 522.3; found 522.4 
 
Solid phase peptide synthesis:  
 Synthesis of peptides was performed on a PSI 200 Peptide Synthesizer (Peptide Scientific 
Inc.) on a Rink amide poly(ethylene glycol) resin (Nova PEG, 0.47 mmol/g). Fmoc-D-amino acids 
(3 eq.) were dissolved in DMF (4 mL) along with NMM (6 eq.) and HCTU (3 eq.). The reaction 
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mixture was agitated for 5 min and added to the solid support for automated coupling and 
deprotection. Coupling times were set to 20 min followed by deprotection of the Fmoc protecting 
group (30 min) with 20% piperidine in DMF. Washing (MeOH and DMF) and drying of the 
peptide bound support with N2(g) were accomplished prior to the recovery of the peptide bound to 
resin. At the N-terminus, Fmoc-aminohexanoic acid (Ahx, 3 eq.) was coupled and Fmoc-
deprotected. Labeling of the Ahx-peptide N-terminus with fluorescein isothiocyanate (FITC, 1.1 
eq.) in pyridine:DMF:DCM (12:7:5 v/v/v) was accomplished in the dark, overnight at room 
temperature. Following synthesis, peptide cleavage from the solid support and deprotection of the 
side-chain protecting groups were accomplished with concentrated trifluoroacetic acid (TFA, 
95%) with minimal addition (5%) of reaction scavengers (i.e. H2O, triethylsilane). The cleavage 
and deprotection reaction was completed in 2 hr at room temperature. Peptide samples were 
concentrated, precipitated in cold diethyl ether, and isolated as white pellets for LC/MS analyses 
and purification. 
Solid-phase bioconjugation: 
Solid-phase bioconjugation of peptide nucleolipid and palmitamide were performed on an oil bath 
reaction apparatus with stirring block. Rink amide poly(ethylene glycol) resin (Nova PEG, 0.47 
mmol/g) was transferred to a reaction vessel and swollen with 500 µl, DMF at 60 ºC for 2 hr. The 
resin was filtered, washed and dried under N2(g) prior to the reaction. Nucleolipid or palmitamide 
(3 eq.) were added in DMF (500 µl) along with NMM (6 eq.) and HCTU (3 eq.). The reaction 
mixture was preactivated for 7 min before slowly added and agitated for 14 h at 60 ºC with peptide 
bound to solid support. Coupling times were set at 20 min followed by deprotection of the Fmoc 
protecting group (30 min) with 20% piperidine in DMF. Washing (MeOH, DMF and DCM) and 
drying of the peptide bound support with N2(g) were accomplished prior to the recovery of the 
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peptide bound to resin. Labeling of the Ahx-peptide N-terminus with fluorescein isothiocyanate 
(FITC, 1.1 eq.) in pyridine:DMF:DCM (12:7:5 v/v/v) was accomplished in the dark, overnight at 
room temperature. Following synthesis, peptide cleavage from the solid support and deprotection 
of the side-chain protecting groups were accomplished with concentrated trifluoroacetic acid 
(TFA, 95%) with minimal addition (5%) of reaction scavengers (i.e. H2O, triethylsilane). The 
cleavage and deprotection reaction was completed in 2 h at room temperature. Peptide samples 
were concentrated, precipitated in cold ether, and isolated as white pellets for LC/MS analyses and 
purification. 
Characterization of peptides by LC/MS: 
Crude peptide pellets were dissolved in MeOH/H2O (50:50 v/v, 1 mL) for LCMS analyses. 
Sample analyses were performed on an Agilent 1100 series ESI-LCMS with a single quadrupole 
mass analyzer and LC conditions used a linear binary gradient 20-80% or 2-82% MeCN/H2O, 
0.1% FA, over 17 min at 25°C. Analytical RP-HPLC was performed using a Waters 2695 
Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) using a linear binary gradient, 20-
80% or 2-82% MeCN/H2O, 0.1% FA, over 17 min at 25°C, with a 1 mL/min flow rate and 
detection at 220 nm and 260 nm. Samples collected after purification were lyophilized to a white 
solid and re-dissolved in 50:50 v/v H2O:MeOH to confirm purity and identity by LCMS analyses. 
Circular Dichroism (CD) Spectroscopy:                                                        
Samples were prepared 12-16 hr ahead of time in H2O:TFE (50:50, v/v, 1 mL) and stored 
at 5 ºC. CD spectra were collected as an average of 3 scans on an Aviv Circular Dichroism (CD) 
spectrophotometer (Model: 62A DS) from 190-260 nm, using 1 nm bandwidth and 0.5 min step 
size at 25 oC. Samples were blank corrected, the data was smoothed and converted to molar 
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ellipticity values from the equation [θ] = θ /cl, where θ is the molar ellipticity (mdeg), c is the 
molar concentration of the peptides (12.5 µM) and l is the path length of the cell (1 cm). The data 
was imported into Microsoft Excel and the CD spectra were plotted in terms of molar ellipticity 
vs wavelength. 
UV/Vis Spectroscopy: 
 The final concentrations of the peptide solutions was determined by UV/Vis 
spectrophotometry at 214 nm ( value of peptides and calculated from the equation:              
 214 = (peptidebond)(npeptidebonds) + Σ (aminoacid(i))(naminoacid(i)).  
The analyses were conducted on an 8452A Diode Array Spectrophotometer from Hewlett Packard, 
with wavelength range set from 190 – 600 nm with maximum absorption collected at 220 and 260 
nm in addition to 490 nm for the FITC-labeled peptides. Peptide concentrations were standardized 
at 12.5 M.  
 Log P values were measured via octanol partitioning by a modification of the shake-flask 
method. An aliquot (200 L, 0.16 mM) of the FITC-labeled peptide samples in Tris buffer (10 
mM, pH 7.4) and 1-octanol (200 L) were added to a 0.5 mL micro tube. Samples were vortexed 
(1 min) and centrifuged. An aliquot of each layer (150 L) was removed and diluted (850 L, 3:1 
v/v methanol:Tris or methanol:octanol) to a final composition of 3:1:1 v/v/v methanol:octanol:Tris 
buffer. The aqueous layer was diluted (30 and a series of three serial dilutions were prepared 
for each phase. The log of the partition coefficient (FITC490nm of the organic layer vs. FITC490nm 
of the aqueous layer) yielded log P values according to UV absorption measurements made at 490 
nm. For compounds with very low lipophilicity (log P ≤ 2.3), the volume of the octanol and water 
was increased from (100 to 125 L), and the absorbance of the octanol layer was measured without 
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any additional dilutions. This procedure was repeated a minimum of three times per sample to 
calculate the mean log P and standard error. All absorbance measurements used were within the 
linear range of the instrument and blank corrected with Tris buffer and distilled water. 
Dynamic Light Scattering (DLS):  
 DLS measurements were performed on Malvern Zetasizer (Malvern Instruments Limited 
ZEN3600). All samples were diluted with pico pure water by ratio of 1:1, 1:4, 1:8, and 1:16. 
Samples were sonicated for 15 minutes before measurement. Results were chosen from the major 
population of the highest quality measurement. 
Transmission Electron Microscopy (TEM): 
 Dilute samples used for DLS measurements were mixed in a 1:1 ratio with 1% uranyl 
acetate, sonicated for 10 minutes. An aliquot (5 µL) was put on a carbon film coated copper grid, 
300 mesh (electron microscopy sciences, Hatfield, PA) and the excess solution was removed 
immediately using absorbent paper. The grids were dried overnight  and viewed under the 
transmission electron microscope (JEOL, model JEM-1200 EX). Images were taken with a SIA–
L3C CCD camera (Scientific Instruments and Applications, Inc.) using the software Maxim DL5 
(Diffraction Limited, Ottawa, Canada). 
Cell Viability: 
 NCI 60 testing is performed in two parts: first a single concentration is tested in all 60 cell 
lines at a single dose of about 10-5 molar or 15 µg/ml. If the results obtained meet the selection 
criteria, then the compound is tested again in all 60 cell lines in 5 x 10 fold dilutions with the top 
dose being about 10-4 molar or 150 µg/ml.  
Concentration Requirements – 1-dose/cancer in vitro program 
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 Peptide samples were prepared in DMSO:glycerol 9:1 v/v at a concentration of about 4 
mM for the one dose assay and about 40 mM for the 5-dose assay. In both cases the solution is 
diluted 1:400, giving a High Test concentration of about 10 or 100 µM, respectively.  
Volume requirements – Pre-screen/cancer in vitro program 
 The cancer screen requires 100 µL for 1 log, 5-dose dilutions of regular compounds and 
75 µL for 1-dose testing. 1-dose testing is done at 1/10th the high concentration of 5-dose testing, 
so the volume requirement is 210 µl + 20% at 40 mM for compounds with molecular weights or 
210 µL + 20% at 60,000 μg/ml = 250 µL for compounds without molecular weights 
(macromolecules) (i.e. less than 10 mg for MW = 1000 or 15 mg for compounds tested as 
weight/volume). 
 For 1-dose 60 cell testing: On the day of or the day before drug addition to growing cells 
in tissue culture, a strip of standards (Adriamycin, NSC 123127 prepared and stored the same as 
the compounds) is added to the detachable well plate, and 90 µL DMSO is added to each well (4 
mM solution), and mixed/sonicated and 75 µL is transferred, using a 12 channel hand pipettor, to 
a 12 channel reservoir plates (column plates), which is sealed and stored under nitrogen in a 
desiccator box until delivered to the testing lab. The labels are placed at the right and the left of 
the front of the reservoir plate. It will be the first and the last NSC number in the row. Rows are 
transferred from detachable plate to columns 3-12 of column plates. Plates are sealed and stored 
under nitrogen no more than 24 hours prior to drug addiction. 
Interpretation of One-Dose Data 
 The one-dose data will be reported as a mean graph of the percent growth of treated cells 
and will be similar in appearance to mean graphs from the 5-dose assay. The number reported for 
71 
 
the one-dose assay is growth relative to the no-drug control, and relative to the time zero number 
of cells. This allows detection of both growth inhibition (values between 0 and 100) and lethality 
(values less than 0). This is the same as for the 5-dose assay, described below. For example, a 
value of 100 means no growth inhibition. A value of 40 would mean 60% growth inhibition. A 
value of 0 means no net growth over the course of the experiment. A value of -40 would mean 
40% lethality. A value of -100 means all cells are dead. Information from the one-dose mean graph 
is available for COMPARE analysis. 
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CHAPTER 3: DIVERSITY ORIENTED SYNTHESIS OF KILLER PEPTIDE 
NUCLEOLIPID BIOCONJUGATES AND THEIR STRUCTURE-ACTIVITY 
RELATIONSHIP STUDIES 
3.1 GENERAL INTRODUCTION 
 Nucleolipid bioconjugates have a wide range of applications including gene therapy, 
medicinal chemistry and for the formulation of biomaterials for the development of 
biotechnologies [1,2]. Their exceptional utility stems from an amphiphilic structure which 
facilitates self-assembly into supramolecular nanoparticle formulations in aqueous and organic 
solutions [3]. The structural features of nucleolipid bioconjugates includes a nucleoside core that 
may participate in H-bonding interactions and hydrophobic lipid appendages which may facilitate 
self-assembly through non-polar interactions. Moreover, nucleolipids may be functionalized with 
reactive functional groups, including carboxylic acids that may participate in amide couplings, 
azide and alkynes that can be used for dipolar cycloaddition chemistry in addition to the 
incorporation of a wide range of electrophiles that may be prone towards nucleophilic substitution 
or cross coupling reactions.  
For example, an amino acyl nucleolipid was synthesized following an optimized EEDQ-
coupling strategy in which a reactive 5’-carboxy derived guanosine derivative was effectively 
coupled to Lys(Boc)CO2Me [4]. The subsequent deblocking of the 2’ and 3’-CBz protecting 
groups by hydrogenolysis followed by esterification of the 2’ and 3’-OH groups with palmitoyl 
chloride afforded the aminoacylnucleolipid. The side-chain Lys(Boc) protecting group was 
removed using acidic conditions to afford a partially protected cationic aminoacyl nucleolipid that 
showed the ability to bind to GRP78 DNA and elicit selective and potent cell death (>90%) in a 
SR leukemia cell line at 10 M [4]. The free-form guanosine aminoacyl nucleoplipids retain the 
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ability to form stable G-tetraplexes in solution [5], while chelating with Li+ and K+ metal ions. 
Interestingly, the self-assembled amphiphiles also produced H+/OH- ion flux in the presence of a 
pH gradient making them potentially useful transporter ligands [5]. In anti-proliferative assays in 
a selected panel of cancer cell lines, the nucleolipids showed modest activities (IC50: 17 - >10
3 
µM) in the MCF-7 breast cancer cells [5]. Similarly, a cationic aminoacyl surfactant was formed 
through a multi-step synthesis strategy, ultimately featuring Mitsonoubu chemistry which yielded 
the reactive 3’-azido xylouracil derivative which was subsequently reduced to the free amino and 
coupled to N-Boc-Pro using carbodiimide coupling conditions [6]. Carbodiimide couplings were 
also used to functionalize the 2’-OH with oleic acid and the 5’-OH with a poly(ethylene) glycol 
chain. The deprotection of the Boc group yielded a cationic amphiphile which formed micelles in 
water and produced weak activities (IC50: 19 – 98 µM) relative to the control cetyl 
triethylammonium bromide (CTAB) in a panel of human, rat and murine cell lines [6]. The 
biological activity of the aminoacyl nucleolipid, was found to occur at concentrations nearing its 
critical micelle concentration (cmc: 40 µM), underscoring the importance of a self-assembled 
nanoparticle formulation for biological activity. Moreover, nucleolipid bioconjugates have been 
used in gene delivery applications [7,8].  For example, synthetic polycationic nucleolipids 
generated by carbonyldiimidazole couplings have been combined siRNA for the formation of 
stable ionic complexes that facilitated delivery and release of siRNA within HeLa cells for 
Vasuclar Endothelial Growth Factor (VEGF) knockdown [7]. The spermine derived amino acyl 
nucleolipid was found to effectively transfect siRNA  (>90% VEGF knockdown) which ultimately 
led to apoptosis (~20%) in HeLa cells. The arginine-linked nucleolipid synthesized from a 1,3-
dipolar cycloaddition formed stable ionic complexes with anti-VEGF siRNA resulting in potent 
VEGF knockdown (>90%) which paralleled the Lipofectamine-based siRNA transfections in 
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HeLa cells [8]. The glycosyl nucleolipids have also formed an interesting class of amphiphiles. In 
a relevant study, a glycosyl nucleolipid was synthesized by the Huisgen copper catalyzed azide-
alkyne 1,3-dipolar cyloaddition reaction which also facilitated the incorporation of alkyne-derived 
fatty alcohols, steroids, terpenoids, fatty esters, amides and fluorinated amides [9]. The glycosyl 
nucleolipids exhibited complementary H-bonding, - stacking and hydrophobic interactions 
which contributed to their cytotoxicities (>70%) even after 72 h incubation with the human 
hepatocarcinoma (Huh-7) cell line. Interestingly, the amphiphiles formed hydrogels with 
distinctive supramolecular self-assemblies, including nanofibers, spheres and semitubular objects 
that were speculated to contribute to their cytotoxicities. Therefore, functionally diverse 
nucleolipids have shown the ability to self-assemble into amphiphilic supramolecular structures 
that were found to be contributive to their anti-cancer activities.  
 Additional nucleolipids containing various modifications are represented in Figure 3.1. 
The nucleotide-based amphiphiles (3.1) were formed from an extension of phosphoramidite 
chemistry, by tetrazole-mediated couplings with fatty long chain alcohols [10]. The resulting 
amphiphiles displayed the capabilities of forming lamellar-type structures held together by H-
bonding interactions as discerned from FT-IR spectroscopy and X-ray diffraction studies. In a 
related example, uridine phosphocholine-based amphiphiles were prepared with myristic, palmitic, 
stearic, arachidic and oleic acids, 3.2 [11]. TEM imaging revealed the formation of small, 
unilamellar vesicles and nanofibers capable of entrapping DNA for potential gene delivery 
applications. More specifically, a uridine based nucleolipid, 3.3, was prepared via a synthetic 
strategy featuring nucleophilic displacement of a reactive 5’-tosylate with trimethylamine to form 
the quaternary ammonium tosylate salt. At the 2’ and 3’-OH groups, carbodiimide couplings 
installed the dioleolyl groups. The cationic nucleolipid formed worm-like structures in aqueous 
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solution and formed multilamellar structures with calf thymus DNA, which was found to be 
intercalated in between the lipid bilayers [12]. In a similar application, a phosphocholine 
nucleolipid, 3.4, was synthesized in a 4-step procedure and was found to effectively form vesicles 
with plasmid DNA [13]. The ability for cationic amphiphilic nucleolipids to readily condense 
nucleic acids into stable nanoparticle formulations paves the way for gene delivery applications in 
gene therapy, biotechnology and in molecular cell biology.    
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Figure 3.1. Synthetic nucleolipids scaffolds (A) deoxythymidine palmitoylphosphate [10] (B) 1,2-
dipalmitoyluridinophosphocholine (DPUPC) [11] (C) (N-[5’,(2’,3’-dioleoyl)uridine-N’,N’,N’-
trimethylammonium tosylate (DOTAU) [12] (D) O-ethyl-dioleylphosphatidylcholinium-uridine 
(O-ethyl-DOUPC) [13].  
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The nucleolipids are based on non-ionic, zwitterionic, and ionic structures that are adaptive 
towards self-assembly and nanoparticle formulation. The alkylamine hydrophobic chain was also 
found to play an important role in the self-assembly process. It provided hydrophobic character to 
the amphiphile that resulted in the self-assembly of topologically defined structures (Figure 3.2). 
Cryo-TEM reveals high resolution imaging of phospholipid nucleosides, including the self-
assembly of polydisperse wormlike micelles for 1,2-dilauroyl-sn-glycerophosphatidyluridine 
(DLPU) in aqueous solution (Figure 3.2 A) [18]. Spontaneous formation of helical structures has 
also been observed for dimyristoyl-5’-phosphatidyldeoxycytidine (DMPcyt) (Figure 3.2 B). The 
electron micrograph of the super helical strands served as proof of self-assembly and formulation 
into discrete, well-defined structures [19]. Related examples include, a palmitoyl phosphate 
nucleolipid, which was found to self-assemble into flat and aggregated motifs, the choline-based 
nucleolipids produced quasi-spherical micelles, whereas the 5’-substituted nucleolipids produced 
micelles, flexible cylindrical aggregates and bilayers based on alkylamine chain length. Short 
chain alkylamines (e.g. (CH2)6 to (CH2)9) formed quasi-spherical micelles and long chain 
alkylamine (e.g. (CH2)10 to (CH2)20) nucleolipids formed flat structures [14-19].  These examples 
serve to illustrate the functionally diverse nature of amphiphilic nucleolipids. Synthetic methods 
have not only facilitated their production but also improved their applications. As such, nucleolipid 
bioconjugates form an interesting class of amphiphiles that retain the ability to self-assemble into 
well-defined high-order nanostructure formulations for a wide range of applications. These include 
but are not limited to their use as responsive biomaterials, as diagnostic and therapeutic probes.  
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Figure 3.2.  Phospholipid-nucleolipid self-assembly into higher-ordered nanostructures. TEM 
images adapted from Allain, V.; Bourgaux, C.; Couvreur, P. Nucleic Acids Res. 2012, 40, 1891-
1903. 
 
3.2 CHAPTER OBJECTIVES 
 The synthesis, characterization and anti-cancer activity of a new class of killer peptide 
bioconjugates was reported in Chapter 2. The nucleolipid derived D-(KLAKLAK)2-AK sequence 
retained an amphiphilic, -helical structure which displayed greater anti-proliferative effects in a 
selective panel of NSCLC when compared to the palmitamide derived peptide and the wild type 
sequence.  In the search for more potent peptide-based anti-cancer conjugates the development of 
new and improved nucleolipid derived D-(KLAKLAK)2-AK sequences are desired. Towards this 
goal, this chapter describes the diversity oriented synthesis of new peptide-nucleolipid conjugates 
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for structure-activity relationship studies (SARs) against cellular tumor targets. Considering a 
reductive amination approach was successfully developed for the synthesis of a hecadecylamine-
derived nucleolipid-peptide conjugate, this approach may be perfectly suitable for the 
incorporation of various small, medium, large chain alkylamine, diamines, unsaturated amines or 
polyamines for exploring SARs. More specifically, these modifications are expected to fine tune 
the amphiphilic poly(cationic) -helical properties of the peptide nucleolipids. These requirements 
are anticipated to improve binding and permeability across the lipid bilayer of malignant tumor 
types. These characteristics are also anticipated to improve peptide accumulation at the 
mitochondria that results in the dissipation of charge, the disruption of organelle integrity and the 
release of pro-apoptotic executors that effect cancer cell death. The proposed mechanism of action 
is described in Figure 3.3. 
 
 
Figure 3.3. Proposed mechanism of action for the peptide nucleolipid bioconjugates. 
 The judicious selection of different alkyl amines, including methylamine and octylamine 
was based on their capabilities to fine tune peptide hydrophobicity and to provide a comparative 
study investigating the influence of alkyl chain length on peptide structure, biophysical and 
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biological properties. Moreover, histamine modifications have also been incorporated for boosting 
immune responses while acting as neurotransmitters by binding to the G-protein coupled histamine 
receptor [14-16]. Thus, histamine derived peptide nucleolipids are expected to trigger multiple 
biological responses in live cancer cells. Polyamines such as 1,3-diamino propane and spermine 
are expected to generate poly(cationic) nucleolipids at physiological pH. This feature is not only 
expected to facilitate peptide internalization and mitochondria localization but also in the delivery 
of poly(anionic) cargo, such as in the delivery of siRNA for RNAi applications. Thus, this chapter 
describes the diversity oriented synthesis strategy for the development of functionally diverse 
carboxy-derived nucleolipids that may then be combined with the killer peptide sequence by our 
well-established solid-phase bioconjugation approach. Peptide nucleolipid bioconjugates will be 
analyzed and purified by LC/MS. Peptide biophysical studies will be determined by RP HPLC and 
UV-Vis spectroscopy while CD spectroscopy will shed insights on the structural properties of the 
bioconjugates. The anti-cancer screen of the bioconjugates will take place in collaboration with 
Hackensack University Medical Center, under the supervision of Dr. Robert Korngold. Mariana 
Phillips (PhD student in the Sabatino group located in the Department of Chemistry and 
Biochemistry) will conduct cell based cytotoxicity studies in the selected tumor cells in order to 
validate a lead peptide-nucleolipid bioconjugate. Taken altogether, these important SAR studies 
are not only pivotal to the identification of peptide-nucleolipid combinations that can effect potent 
cancer cell death, but also in the selection of a lead bioconjugate that can be functionalized with 
cancer-targeting ligands for the selective treatment of tumors. The latter is a focus of current and 
future studies aimed towards the development of selective and potent peptide anti-cancer drugs 
(Chapter 4).   
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3.3 SYNTHESIS AND CHARECTERIZATION OF PEPTIDE-NUCLEOLIPID 
BIOCONJUGATES. 
3.3.1. RATIONAL DESIGN OF PEPTIDE-NUCLEOLIPID BIOCONJUGATES  
The rational design of a library of peptide-nucleolipid bioconjugates was developed in this 
study (Figure 3.4). The nucleolipid scaffold was designed with diverse functional groups 
including alkylamines with varying chain lengths (e.g. methylamine, octylamine and 
hexadecylamine) to explore the influence of hydrophobicity on peptide structure and activity. 
Moreover, alkyl diamines and polyamines (e.g. diamino propane and spermine) were also included 
as functional groups that were anticipated to bear polycations at physiological pH. The latter 
encompasses an important requirement for cell permeability and mitochondrial localization that 
ultimately results in cellular cytotoxicity [20]. Furthermore, cyclic amines such as histamine were 
also included in our proposed design to fine-tune the amphiphilic nature of the nucleolipid while 
potentially triggering interesting biological activities inside cells [21]. The functionally diverse 
nucleolipids were also designed with a reactive 5’-carboxy group which would facilitate coupling 
to the -amino group of the C-terminal Lys within the D-(KLAKLAK)2-AK sequence. At the N-
terminus, the peptide sequence is lengthened by an aminohexanoic acid linker (AHx) which is 
necessary for the efficient incorporation of the fluorescein isothiocyanate (FITC) fluorescent tag 
for imaging biological activity inside cells [22]. In this manner, the newly designed D-
(KLAKLAK)2-AK nucleolipid bioconjugates (Figure 3.4) would serve to explore the influence of 
structurally diverse nucleolipids on the biological activity of the killer peptide sequence. These 
studies are not only important for determining structure-activity relationships but also in 
identifying a lead that can be further optimized into an anti-cancer therapeutic.  
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Figure 3.4. Design of killer peptide nucleolipid bioconjugates. Figure adapted from Rana, N., 
Huang, S.; Patel, P.; Samuni, U.; Sabatino, D. Bioorg. Med. Chem. Lett., 2016, 26, 3567–3571.    
 
3.3.2. DIVERSITY ORIENTED SYNTHEIS OF NUCLEOLPIDS 
 The 3’-aldehyde derived thymidine, 3.5, was selected as the reactive precursor for the 
diversity oriented synthesis of functionally diverse nucleolipids (Figure 3.5). In this synthesis 
method, the reductive amination approach was optimized with functionally diverse amines for 
yielding nucleolipids 3.6-3.10. The reductive amination with methylamine and octylamine 
proceeded smoothly according to TLC. However, difficulties associated with extraction and 
chromatographic purification limited yield recoveries. Nonetheless, the alkylamine-derived 
nucleolipids, 3.6-3.7, were recovered in sufficient quantities (14-32% yields) for their conversion 
into the desired 5-carboxy derived nucleolipids as described in Scheme 3.1. The histamine, 
spermine and N-Boc diaminopropoane derived nucleolipids (3.8-3.10) proved more difficult to 
make. In these cases, the formation of side products, presumably due to the reactive amino 
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functionalities were detected by TLC and difficulties associated with recoveries following 
extraction and purification resulted in low yields (8-20%). The isolated products were analyzed 
and characterized by a combination of 1H, 13C NMR and mass spectrometry.         
 
 
 
Figure 3.5. Diversity oriented synthesis of various nucleolipids by the reductive amination 
approach. 
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The diversity oriented synthesis strategy for the various nucleolipids developed in this 
study is based on the reductive amination approach which ultimately yielded the 5’-carboxy 
derived nucleolipids 3.16-3.20 (Scheme 3.1). Following quantitative removal of the 5’-DMT 
group using trichloroacetic acid (TCA), a TEMPO-mediated oxidation reaction converted the 5’-
hydroxy group to the carboxylic acids, 3.16-3.20. Each reaction intermediates and the final 
products were characterized by 1H and 13C NMR, IR spectroscopy and by MS to confirm purities 
and identities for the incorporation of the 5’-carboxy derived nucleolipids 3.16-3.20 within the 
killer D-(KLAKLAK)2-AK sequence. 
 
Scheme 3.1. Solution phase synthesis of the 5’-carboxy derived nucleolipids, 3.16-3.20. 
  
3.4 DESIGN, SOLID PHASE BIOCONJUGATION AND CHARACTERIZATION OF 
(FITC)-AHX-D-(KLAKLAK)2-AK-NUCLEOLIPIDS 
3.4.1. DESIGN OF NOVEL AHX-D-(KLAKLAK)2-AK-NUCLEOLIPIDS 
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The novel peptide nucleolipids consist of trifunctional bioconjugates (Figure 3.6). They 
contain an N-terminal AHx-linked FITC fluorophore for fluorescent imaging and detection 
applications in live cancer cells. The D-(KLAKLAK)2 peptide encompasses the killer peptide 
sequence while the C-terminal AK sequence contains a Lys(Dde) residue that can be removed 
under orthogonal deprotection conditions to reveal the reactive side chain amino group for 
bioconjugation. Solid phase bioconjugation of the support-bound D-(KLAKLAK)2-AK sequence 
with the carboxy derived nucleolipids is anticipated to provide a small library of peptide-
nucleolipid conjugates for exploring structure-activity relationships in cancer. 
 
Figure 3.6. Peptide-nucleolipid structures. The D-(KLAKLAK)2-AK peptide scaffold with 
R1(red) = H or FITC, R2(blue) = Nucleolipid where R = CH3, (CH2)7CH3, (CH2)15CH3, 
(CH2)3NH(CH2)4NH(CH2)3NH2, (CH2)3NH2, and histamine. All amino acids are in their D-
configuration. 
3.4.2. SOLID PHASE BIOCONJUGATION 
 The solid phase bioconjugation approach has been developed to actively couple potent and 
reactive drug like molecules or biologicals onto the solid support e.g. resin, bead, or mica surface. 
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A suitable solid support was first selected based on sequence compatibility and synthetic 
efficiency. The poly(ethylene glycol) (PEG) based resins have proven to be especially useful in 
the synthesis of lengthy and hydrophobic peptides that have the tendency to aggregate during the 
solid phase synthesis procedure. The excellent swelling properties of PEG-based resins in organic 
solvents such as DMF and acids such TFA have been shown to improve synthetic efficiency and 
recoveries following solid phase peptide synthesis [24]. In our approach, the D-(KLAKLAK)2-AK 
sequence was synthesized on the Rink amide PEG resin for generating C-terminal peptide amides. 
The C-terminal Lys residue contained the Dde protecting group that has been shown to 
orthogonally deblock using buffered hydroxylamine hydrochloride that promotes the 
transamination reaction of the support-bound peptide sequence [25]. In our approach, 
hydroxylamine hydrochloride was buffered and solubilized in imidazole and NMP/DMF, 
respectively, for selectively unmasking the Lys side chain Dde group. This reaction was closely 
monitored by LC-MS that produced 60-80% conversions on solid phase. An Fmoc protecting 
group at the N-terminus directed the coupling of the 5’-carboxy-derived nucleolipids at the C-
terminus Lys side chain amino group. A HCTU-mediated coupling reaction (Scheme 3.2) was 
used to couple the nucleolipids to the support-bound peptide sequence. Following solid-phase 
bioconjugation, Fmoc deprotection using basic piperidine followed by FITC coupling at the N-
terminal AHx linker produced the FITC-labeled peptide-nucleolipid bioconjugates on solid phase. 
Of note, peptide-nucleolipid bioconjugates were also produced without the FITC label. In these 
cases, a portion of the Fmoc-AHx-D-(KLAKLAK)2-nucleolipid bound resin was Fmoc deblocked 
followed by cleavage and deprotection of the bioconjugate from solid phase. The TFA-mediated 
cleavage and deprotection conditions were also employed for isolating the FITC-labeled 
bioconjugates from solid phase. Control peptides with and without the FITC/nucleolipids were 
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also produced in order to determine the influence of the modifiers on peptide structure and 
biological activities. The isolated peptide-nucleolipid bioconjugates were analyzed and purified 
by RP HPLC (Table 3.2). The identities of the pure bioconjugates were confirmed by LC-MS for 
SAR studies.     
 
Scheme 3.2. Solid phase synthesis of FITC and non-FITC tagged D-(KLAKLAK)2-AK with 
nucleolipids. 
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Entry Sequence 
and 
Number 
aCrude 
Purity(%) 
bIsolated 
Purity(%) 
cIsolated 
Yield(%/mg) 
dM.W. 
(g/mol) 
Actual(e) 
eZ fRT 
(min) 
MeOH 
gRT 
(min) 
MeCN 
1 AHx-D-
(KLAKLAKKLAKLAK)-
AK-Methylamine 
nucleolipid, 3.22 
70 99 67/10 533.6 
(533.1) 
4 10.6 9.7 
2 AHx-D-
(KLAKLAKKLAKLAK)-
AK-Octylamine 
nucleolipid, 3.23 
55 96 80/9 446.3 
(446.7) 
5 11.2 8.9 
3 AHx-D-
(KLAKLAKKLAKLAK)-
AK-Histamine 
nucleolipid, 3.24 
78 95 79/12 386.0 
(386.2) 
6 9.3 5.7 
4 AHx-D-
(KLAKLAKKLAKLAK)-
AK-Spermine nucleolipid, 
3.25 
83 96 80/9 576.5 
(576.2) 
4 12.0 10.1 
5 AHx-D-
(KLAKLAKKLAKLAK)-
AK-1,3-diaminopropane 
nucleolipid, 3.26 
90 97 54/7.5 544.4 
(544.4) 
4 11.9 7.4 
6 FITC-AHx-D-
(KLAKLAKKLAKLAK)-
AK-Methylamine 
nucleolipid, 3.27 
85 >99 45/8 505.0 
(505.7) 
5 13.2 11.1 
7 FITC-AHx-D-
(KLAKLAKKLAKLAK)-
AK-Octylamine 
nucleolipid, 3.28 
86 >99 60/9.5 524.8 
(524.6) 
5 15.0 12.3 
8 FITC-AHx-D-
(KLAKLAKKLAKLAK)-
AK-Histamine 
nucleolipid, 3.29 
90 >99 71/6 521.8 
(521.0) 
5 12.3 12.0 
9 FITC-AHx-D-
(KLAKLAKKLAKLAK)-
AK-Spermine nucleolipid, 
3.30 
93 98 80/5.5 539.6 
(539.2) 
5 13.3 9.8 
10 FITC-AHx-D-
(KLAKLAKKLAKLAK)-
AK-1,3-diaminopropane 
nucleolipid, 3.31 
75 >99 73/7.8 641.4 
(641.8) 
4 15.0 14.5 
 
Table 3.2. Characterization data of peptide nucleolipid bioconjugates. aCrude purities by RP-
HPLC at 220 nm. bIsolated purities by RP-HPLC at 220 nm using 2-80% MeOH/H2O with 0.1% 
FA over 17 min. cIsolated yields based on the resin loading. dObserved mass (expected mass) as 
[M+H]+/Z as detected by LCMS. eCharged state of the peptides as detected by LCMS in positive 
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mode. fRetention times using 2-80% MeOH/ H2O with 0.1% FA over 17 min. 
gRetention times 
using 2-80% MeCN/H2O with 0.1% FA over 17 min.
  
 
3.4.3. CHARACTERIZATION OF PEPTIDE NUCLEOLIPID BIOCONJUGATES 
The hydrophilicities of the peptide bioconjugates were confirmed by RP HPLC (Figure 
3.7). In our analysis, the histamine-derived peptide nucleolipid bioconjugate (3.24) eluted fastest 
on the C18 RP HPLC column (rt: 9.3 min) during the acidic RP HPLC conditions (i.e. 2-80% 
MeOH/H2O 0.1% FA). This result suggests that the heterocycle fine-tunes the amphiphilic nature 
of the nucleolipid. Furthermore, the ionizable imidazole is also anticipated to be protonated during 
the RP HPLC conditions further contributing to the polar, polycationic nature of the sequence. The 
polyamine derived peptide-nucleolipid bioconjugates (3.25 and 3.26) proved to be most 
hydrophobic and retained (rt: 12.0 min and 11.9 min, respectively) indicating that the lengthy, 
aliphatic hydrocarbon polyamine chain of the nucleolipid provided a more non-polar contribution 
to the bioconjugate. Presumably, this factor outweighs the polar contribution of the polycationic 
polyamine using the same eluent gradient conditions on the C18 RP column. The methyl- and 
octyl-amine derived peptide nucleolipids (3.22, 10.6 min and 3.23, 11.2 min, respectively) were 
also found to be hydrophobic and retained sequences on the C18 RP column, albeit to a lesser 
extent when compared to the polyamine-derived nucleolipid bioconjugates (3.25 and 3.26). Taken 
together, the nucleolipids contribute variable effects on the polarity of the D-(KLAKLAK)2-AK 
sequence that may influence their structure, formulation and biological activity in cell culture 
conditions.  
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Figure 3.7. Comparative RP HPLC analysis of the nucleolipid-derived D-(KLAKLAK)2-AK, 
bioconjugates (3.22-3.26). 
Furthermore, UV-Vis spectroscopy confirmed the characteristic absorption bands of the 
peptide bonds (λmax ~ 220 nm), thymine base (λmax ~ 260 nm) and the FITC label (λmax ~ 450 nm) 
corresponding to the nucleolipid-derived D-(KLAKLAK)2-AK, bioconjugates (Figure 3.8). 
 
Figure 3.8. Comparative UV-Vis spectroscopy (190-310 nm) of the nucleolipid-derived D-
(KLAKLAK)2-AK, bioconjugates (3.22-3.26) and (3.27-3.31). 
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CD spectroscopy was then used to evaluate the secondary structures (if any) of the peptides 
in H2O:TFE. The combination of H2O:TFE has served to mimic the amphiphilic lipid bilayer 
microenvironment that may stabilize peptide secondary structures [26]. In this study, the methyl- 
and octyl-amine nucleolipid derived D-(KLAKLAK)2-AK sequence, 3.22 and 3.23, respectively, 
displayed stable, α-helical secondary structure (40-65% helicity), while the histamine nucleolipid 
derived D-(KLAKLAK)2-AK, 3.24, displayed enhanced helicity (65-76%) and the polyamine 
nucleolipid derived D-(KLAKLAK)2-AK 3.25 and 3.26, demonstrated a less stable (<40%) α -
helical secondary structure (Figure 3.9). Many amphiphilic cell-penetrating peptides adopt α-
helical secondary structures. This peptide motif may functions as a recognition site with other 
membrane spanning proteins facilitating cellular permeability [27]. 
  
Figure 3.9. CD spectroscopy of the peptide-nucleolipid bioconjugates (3.22-3.26) in TFE:H2O 
(1:1 v/v, 12.5 M). 
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3.5. BIOLOGICAL ACTIVITIES OF THE NUCLEOLIPID-PEPTIDE BIOCONJUGATES 
3.5.1. CYTOTOXICITIES IN MM1S MELANOMA CANCER CELLS 
The cytotoxic activities of the nucleolipid-peptide bioconjugates (3.22-3.26) were 
evaluated within the MM.1S human multiple myeloma B cell lymphoblast culture, known to be a 
clinically relevant tumor model for evaluating the anti-cancer effects of new drug candidates [28]. 
The MM.1S cell culture and testing of the synthetic bioconjugates was accomplished by Mariana 
Phillips and Chris Cultrara, PhD students in the laboratory of Dr. David Sabatino (Department of 
Chemistry and Biochemistry, SHU). A Guava Nexin® Reagent (EMD Millipore) was used to 
assess early and late-stage apoptosis by flow cytometry [29].  In this assay, the MM.1S cells were 
incubated for 24 hours with the bioconjugates (3.22-3.26, 2.5 M in PBS buffer). After incubation, 
the cells were centrifuged, washed and stained with the Guava Nexin® Reagent to determine the 
MM.1S cells’ viability using flow cytometry. The results showed early and late stage apoptotic 
events for the MM.1S cells when treated with the histamine-derived nucleolipid-peptide 
bioconjugate 3.24, (Figure 3.10) making it a lead for further biological evaluation.  The remaining 
bioconjugates did not exhibit toxicity in this assay.   
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Figure 3.10. Peptide-nucleolipid bioconjugate effects on the MM1S cells’ viability according to 
the Guava Nexin Reagent using flow cytometry. 
3.6 CONCLUSIONS 
 In conclusion, a versatile diversity-oriented synthesis approach for the generation of a small 
library of novel peptide-nucleolipid bioconjugates is described in this chapter. The methodology 
underscores a flexible and adaptive reductive amination approach for installing a variety of alkyl, 
cyclic and polyamines into a nucleoside scaffold for formulating structurally diverse nucleolipids 
for exploring SAR studies. The nucleolipids were functionalized with a reactive 5’-carboxy group 
which facilitated bioconjugation on solid support with the cytotoxic D-(KLAKLAK)2-AK 
sequence. The peptide-nucleolipid bioconjugates were found to exhibit tunable biophysical and 
structural properties that were influenced by the nature of the nucleolipid group. In general, the 
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bioconjugates maintained amphiphilic, -helical characteristics which were anticipated to 
contribute to their biological activities in live cancer cells. A single dose (2.5 M) screen against 
the MM.1S multiple myeloma cancer cells revealed a lead peptide that was contributive towards 
early and late stage apoptotic events. This lead potentially encompasses a new class of peptide-
based anti-cancer drugs. 
 
3.7. EXPERIMENTAL SECTION 
3.7.1. SYNTHESIS 
5’-O-(dimethoxytrityl) 3’-O-(methylaminoethyl) thymidine [3.6]: The starting material 3.5 
(200 mg, 0.34 mmol) and methylamine (11.2 µL, 0.32 mmol) were dissolved in 3 mL of dry THF. 
The reaction was stirred for 20 min at room temperature and sodium cyanoborohydride (26 mg, 
0.41 mmol, 1.2 equiv) was added to reaction mixture and stirred for 4.5 hrs. The reaction was then 
concentrated in vacuo and purified by flash column chromatography using EtOAc:Petroleum ether 
(9:1 v/v) to yield a white foamy product 3.6 in 32% yield. m.p. 60 °C. [𝛼]589
22 : +12.11 (c 0.01, 
DCM). Rf = 0.60 (EtOAc–petroleum ether, 9:1 v/v). IR (KBr) υmax (cm-1) = 5994.0, 5978.8, 5966.7, 
5948.3, 5937.3, 5920.7, 5913.2, 5895.0, 5886.7, 5871.7, 5863.0, 5833.2, 5843.4, 5773.8, 5757.6, 
5743.1, 5579.2, 5467.3, 5317.1, 5205.1, 5161.5, 5155.3, 5077.3, 5025.6, 4960.5, 3750.9, 3744.9, 
3737.1, 3712.1, 2376.1, 2347.0, 1507.4, 1275.2, 764.2, 749.5. 1H NMR (499.79 MHz, CD2Cl2): δ 
= 0.92 (t, J  = 6.0 Hz, 3H), 1.34 (t, J  = 12 Hz, 3H) , 1.50 (d, J  = 12.0 Hz, 3H), 1.57 (s, 1H), 2.27 
(m, 1H), 2.40 (t, J  = 6.0 Hz, 1H), 2.78 (d, J  = 8.0 Hz, 1H), 2.99 (m,  2H), 3.31 (m, 1H), 3.40 (d, 
J = 11 Hz, 1H), 3.61 (m, 1H), 3.70–3.81 (m, 8H), 4.10 (dd, J  = 2, 14.5 Hz, 1H), 4.20 (d, J  = 5.0 
Hz, 1H), 6.24 (m, 1H), 6.86 (m, 4H), 7.24-7.33 (m, 7H), 7.41 (d, J  = 10.0 Hz, 2H), 7.50 (m, 1H). 
13C NMR (125.68 MHz, CD2Cl2): δ = 11.6, 37.3, 63.5, 72.3, 80.9, 83.5, 84.6, 84.7, 87.0, 110.9, 
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111.2, 113.1, 113.3, 127.0, 128.0, 129.9, 130.0, 135.2, 135.2, 135.3, 135.5, 144.4, 144.5, 144.6, 
150.3, 158.9, 163.4. ESI MS (m/z) calculated for C34H41N3O7  [M+H], 602.7; found 602.6. 
5’-O-(dimethoxytrityl) 3’-O-(octylaminoethyl) thymidine [3.7]: The starting material 3.5 (200 
mg, 0.340 mmol) and octylamine (54 µL, 0.323 mmol) were dissolved in 3 mL of dry THF. The 
reaction was stirred for 30 min at room temperature and sodium cyanoborohydride (26 mg, 0.409 
mmol, 1.2 equiv) was added to reaction mixture and stirred for 4.5 hrs. The reaction was then 
concentrated in vacuo and purified by flash column chromatography using EtOAc:Petroleum ether 
(6:4 v/v) to yield a white foamy product 3.7 in 14% yield. m.p. 67 °C. [𝛼]589
23.6: +38.04 (c 0.01, 
Acetone). Rf = 0.80 (EtOAc–petroleum ether, 6:4 v/v). IR (KBr) υmax (cm-1) = 2346.8, 1748.4, 
1715.1, 1704.9, 1681.9, 1669.4, 1647.0, 1569.5, 1575.6, 1558.0, 1540.3, 1521.1, 1506.7, 1489.3, 
1275.3, 1261.1, 764.2, 749.8. 1H NMR (499.84 MHz, CD2Cl2): δ = 1.10 (t, J  = 7.0 Hz, 3H), 1.32 
(t, J  = 10.5 Hz, 16H) , 1.52 (d, J  = 7.0 Hz, 3H), 1.50 (s, 1H), 2.21 (m, 1H), 2.42 (t, J  = 7.0 Hz, 
1H), 2.679 (d, J  = 2.0 Hz, 1H), 3.00 (m,  2H), 3.33 (m, 1H), 3.42 (d, J = 7 Hz, 1H), 3.62 (m, 1H), 
3.71–3.82 (m, 8H), 4.11 (dd, J  = 2.0 Hz, 1H), 4.21 (d, J  = 5.0 Hz, 1H), 6.29 (t, 1H), 6.90 (d, 4H), 
7.22-7.32 (m, 7H), 7.53 (d, J  = 10.0 Hz, 2H), 7.43 (s, 1H). 13C NMR (125.6 MHz, CD2Cl2): δ 
=5.1, 7.7, 11.7, 21.9, 22.6, 25.7, 29.0, 31.6, 37.5, 47.0, 55.2, 62.4, 63.8, 72.2, 80.9, 92.4, 110.0, 
111.1, 113.3, 128.0, 129.9, 132.2, 135.2, 143.0, 147.1, 150.2, 154.8, 158.8, 165.3, 178.7, 182.1, 
217.6, 231.8. ESI MS (m/z) calculated for C41H54N3O7  [M+H], 699.8; found 699.9. 
5’-O-(dimethoxytrityl) 3’-O-(histamineoethyl) thymidine [3.8]: The starting material 3.5 (200 
mg, 0.340 mmol) and histamine (36 mg, 0.323 mmol) were dissolved in 3 mL of dry THF. The 
reaction was stirred for 20 min at room temperature and sodium cyanoborohydride (26 mg, 0.409 
mmol, 1.2 equiv) was added to reaction mixture and stirred for 4 hrs. The reaction was then 
concentrated in vacuo and purified by flash column chromatography using EtOAc:Petroleum ether 
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(9:1 v/v) to yield a white foamy product 3.8 in 8% yield. m.p. 90 °C. [𝛼]589
23.8: +204.4 (c 0.01, 
DCM). Rf = 0.75 (EtOAc–petroleum ether, 9:1 v/v). IR (KBr) υmax (cm-1) = 3492.2, 2347.5, 2174.8, 
1733.8, 1677.5, 1658.7, 1641.8, 1631.3, 1557.4, 1540.8, 1502.6, 1440.0, 1391.0, 1251.7, 1178.4, 
1104.9. 1H NMR (499.9 MHz, CD2Cl2): δ = 1.0 (t, J  = 4.0 Hz, 3H), 1.35 (m, 4H) , 1.50 (d, J  = 
12.0 Hz, 3H), 1.57 (s, 1H), 2.23 (m, 1H), 2.46 (t, J  = 6.0 Hz, 1H), 2.84 (d, J  = 7.9 Hz, 2H), 3.00 
(m,  2H), 3.34 (m, 1H), 3.47 (d, J = 11 Hz, 1H), 3.65 (m, 1H), 3.75–3.81 (m, 6H), 4.11 (dd, J  = 2, 
14.5 Hz, 1H), 4.80 (d, J  = 5.0 Hz, 1H), 6.28 (m, 1H), 6.85 (m, 4H), 7.24-7.33 (m, 7H), 7.41 (d, J  
= 10.0 Hz, 1H), 7.0 (s, 1H), 8.73 (m, 1H), 11.3 (m, 1H), 13.0 (m, 1H). 13C NMR (125.6 MHz, 
CD2Cl2): δ =  7.7, 11.7, 22.6, 25.7, 29.0, 31.6, 55.2, 55.3, 62.4, 63.8, 80.9, 92.4, 110.0, 111.1, 
113.3, 128.0, 129.9, 130.0, 135.2, 150.2, 158.8. ESI MS (m/z) calculated for C38H44N5O7  [M+H], 
681.7; found 681.8.  
5’-O-(dimethoxytrityl) 3’-O-(spermineoethyl) thymidine [3.9]: The starting material 3.5 (200 
mg, 0.340 mmol) and spermine (66 mg, 0.323 mmol) were dissolved in 3 mL of dry THF. The 
reaction was stirred for 20 min at room temperature and sodium cyanoborohydride (26 mg, 0.409 
mmol, 1.2 equiv) was added to reaction mixture and stirred for 4 hrs. The reaction was then 
concentrated in vacuo and purified by flash column chromatography using EtOAc:Methanol (9:1 
v/v) to yield a white foamy product 3.9 in 20% yield. m.p. 85 °C. [𝛼]589
23 : +35.5 (c 0.01, DCM). Rf 
= 0.10 (EtOAc–Methanol, 9:1 v/v). IR (KBr) υmax (cm-1) = 5533.1, 5465.0, 3501.1, 3550.3, 3473.4, 
3300.0, 2376.6, 2347.0, 1868.4, 1843.9, 1829.5, 1810.3, 1800.3, 1791.7, 1780.1, 1771.0, 1748.3, 
1739.8, 1714.1, 1705.6, 1683.1, 1669.8, 1662.4, 1647.0, 1635.6, 1507.3, 1454.6, 1423.6, 1365.6, 
1219.5, 1034.9. 1H NMR (499.84 MHz, CD2Cl2): δ = 1.0 (m, 3H), 1.30 (t, J  = 10.5 Hz, 2H) , 1.38 
(m, 4H), 1.48 (d, J  = 10.0 Hz, 3H), 1.57 (s, 1H), 2.23 (m, 1H), 2.46 (t, J  = 6.0 Hz, 1H), 2.53 (m, 
10H), 2.81 (d, J  = 8.0 Hz, 1H), 3.00 (m,  2H), 3.33 (m, 1H), 3.44 (d, J = 11 Hz, 1H), 3.49 (d, J = 
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6 Hz, 2H), 3.64 (m, 1H), 3.75–3.83 (m, 8H), 4.11 (dd, J  = 2, 14.5 Hz, 1H), 4.21 (d, J  = 5.0 Hz, 
1H), 6.29 (m, 1H), 6.85 (m, 4H), 7.24-7.33 (m, 7H), 7.41 (d, J  = 10.0 Hz, 2H), 7.43 (s, 1H). 13C 
NMR (125.6 MHz, CD2Cl2): δ = 12.4, 25.3, 27.3, 25.3, 38.2, 39.4, 49.6, 49.0, 46.3, 48.1, 55.8, 
63.9, 68.8, 82.0, 89.3, 94.8, 110.9, 114.8, 126.2, 127.5, 128.2, 129.2, 136.0, 150.8, 158.1, 163.7,  
ESI MS (m/z) calculated for C43H61N6O7  [M+H], 772.4; found 772.5. 
5’-O-(dimethoxytrityl) 3’-O-(N-Boc-1,3-diamineoethylpropane) thymidine [3.10]: The 
starting material 3.5 (200 mg, 0.34 mmol) and N-Boc-1,3-diaminopropane (56.2 mg, 0.32 mmol) 
were dissolved in 3 mL of dry THF. The reaction was stirred for 20 min at room temperature and 
sodium cyanoborohydride (26 mg, 0.41 mmol, 1.2 equiv) was added to reaction mixture and stirred 
for 4 hrs. The reaction was then concentrated in vacuo and purified by flash column 
chromatography using EtOAc:Methanol (9:1 v/v) to yield a white foamy product 3.10 in 9% yield. 
m.p. 80 °C. [𝛼]589
23.8: +9.16 (c 0.01, DCM). Rf = 0.10 (EtOAc–Methanol, 9:1 v/v). IR (KBr) υmax 
(cm-1) =3514.2, 1791.0, 1771.6, 1721.0, 1710.6, 1635.6, 1608.6, 1557.9, 1540.9, 1511.6, 1422.5, 
1365.6, 1222.6, 1177.7, 1092.6, 831.4. 1H NMR (499.79 MHz, CD2Cl2): δ = 1.42 (t, J  = 7.0 Hz, 
3H), 1.50 (d, J  = 12.0 Hz, 3H), 1.57 (s, 1H), 1.74 (m, 2H),  2.33 (d, J = 11.0 2H), 2.38 (m, 3H), 
2.46 (t, J  = 6.0 Hz, 1H), 2.53 (t, J  = 6.0 Hz, 2H), 2.81 (d, J  = 8.0 Hz, 1H), 3.18 (m,  2H), 3.33 
(m, 1H), 3.49 (d, J = 11 Hz, 2H), 3.64 (m, 1H), 3.76–3.81 (m, 8H), 4.11 (d, J  = 2, 14.5 Hz, 1H), 
4.21 (dd, J  = 5.0 Hz, 1H), 6.29 (m, 1H), 6.85 (m, 4H), 7.24-7.33 (m, 7H), 7.19 (d, J  = 10.0 Hz, 
1H), 11.32 (s, J  = 5.0 Hz, 1H) 13C NMR (125.6 MHz, CD2Cl2): δ = 22.2, 25.4, 25.9, 26.3, 29.1, 
29.3, 29.3, 29.2, 29.6, 31.9, 53.0, 53.1, 53.4, 53.6, 53.8, 55.2, 55.3, 96.0, 97.3, 99.8, 111.1, 113.2, 
128.0, 130.0, 131.0, 135.3, 135.4, 158.9, 195.8. ESI MS (m/z) calculated for C41H52N4O9Na  
[M+Na], 767.3; found 767.0. 
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5’-hydroxy 3’-O-(methylaminoethyl) thymidine [3.11]: A solution of 3% TCA in DCM (10 mL) 
was added dropwise at room temperature to [3.6] (100 mg, 0.166 mmol). The reaction was 
continued for 3 hr until complete consumption of starting material was detected by TLC. The crude 
product was extracted in DCM/water and the aqueous phase was isolated, freeze-dried and 
lyophilized to dryness. The crude product was purified by silica gel column chromatography 
(EtOAc:Petroleum ether, 6:4 v/v) to obtain >99% of a white foamy product [3.11]. m.p. 67 °C.  
[𝛼]589
25  +12.65 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm-1) = 
3734.5, 3710.5, 3633.7, 3180.3, 2597.7, 2260.9, 1688.4, 1843.8, 1754.8, 1406.6, 1228.2, 845.6, 
683.9 1H NMR (499.9 MHz, CD2Cl2): δ = 0.82 (t, J  = 7.25 Hz, 2H), 1.24 (s, 3H),  1.62 (bs, 1H), 
1.80 (s, 3H), 2.23 (d, J  = 6.5 Hz, 1H), 2.22-2.25 (m, 1H), 2.52 (s, 2H), 2.70 (d, J  = 5.0 Hz, 1H), 
2.76 (t, J  =  5.25 Hz, 1H), 2.90 (t, J  = 7.25 Hz, 1H), 3.60 (s, 1H), 3.70 (s, 1H), 4.0 (m, 1H), 4.10 
(d, J = 3.0 Hz, 1H), 6.51 (bs, 1H),  6.14- 6.17 (m, 1H), 7.71 (s, 1H), 11.19 (s, 1H). 13C NMR (126.9 
MHz, CD2Cl2): δ = 12.0, 14.7, 22.1, 24.9, 26.8, 28.0, 29.8, 38.6, 52.0, 53.2, 62.0, 64.4, 68.3, 80.0, 
80.7, 83.1, 110.0, 136.3, 138.4, 151.0, 164.1, 161.8, 165.2. ESI MS (m/z) calculated for 
C13H22N3O5  [M+H], 300.3; found 300.5. 
5’-hydroxy 3’-O-(octylaminoethyl) thymidine [3.12]: A solution of 3% TCA in DCM (10 mL) 
was added dropwise at room temperature to [3.7] (100 mg, 0.142 mmol). The reaction was 
continued for 3 hr until complete consumption of starting material was detected by TLC. The crude 
product was extracted in DCM/water and the aqueous phase was isolated, freeze-dried and 
lyophilized to dryness. The crude product was purified by silica gel column chromatography  
(EtOAc:Petroleum ether, 6:4 v/v) to obtain >95% of a white foamy product [3.12]. m.p. 70 °C.  
[𝛼]589
22.4 +5.5 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm-1) = 
3433.3, 2252.7, 2126.7, 1843.9, 1792.0, 1771.9, 1733.7, 1658.7, 1642.1, 1401.5, 1027.5, 824.3, 
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762.2. 1H NMR (499.9 MHz, CD2Cl2): δ = 1.10 (d, J  = 11 Hz, 2H), 1.26 (s, 16H),  1.61 (bs, 1H), 
1.79 (s, 3H), 2.14 (d, J  = 6.5 Hz, 1H), 2.22-2.25 (d, J  = 7.25 Hz, 1H), 2.52 (s, 1H), 2.69 (d, J  = 
5.0 Hz, 1H), 2.76 (t, J  =  5.25 Hz, 1H), 2.90 (t, J  = 4.25 Hz, 2H), 3.60 (s, 1H), 3.70 (s, 1H), 4.2 
(bs, 1H), 4.4 (bs, J = 3.0 Hz, 1H), 6.89 (bs, 1H),  6.5 (m, 1H), 7.98 (s, 1H), 11.56 (s, 1H). 13C 
NMR (126.9 MHz, CD2Cl2): δ = 11.9, 12.2, 22.5, 24.2, 25.0, 29.0, 29.1, 31.1, 36.6, 51.0, 52.2, 
62.0, 63.4, 80.2, 80.1, 84.1, 84.6, 115.0, 138.9, 151.0, 165.2. ESI MS (m/z) calculated for 
C20H36N3O5  [M+H], 398.2; found 398.9. 
5’-hydroxy 3’-O-(histaminoethyl) thymidine [3.13]: A solution of 3% TCA in DCM (10 mL) 
was added dropwise at room temperature to [3.8] (100 mg, 0.146 mmol). The reaction was 
continued for 3 hr until complete consumption of starting material was detected by TLC. The crude 
product was extracted in DCM/water and the aqueous phase was isolated, freeze-dried and 
lyophilized to dryness. The crude product was purified by silica gel column chromatography 
(EtOAc:Petroleum ether, 6:4 v/v) to obtain >92% of a white foamy product [3.13]. m.p. 75 °C.  
[𝛼]589
22.5 +147.4 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm-1) = 
3523.1, 3500.2, 3129.5, 2900.3, 2692.4, 2529.6, 2319.3, 1843.9, 1754.1, 1631.5, 1348.3, 1254.3, 
1083.4, 844.3, 677.9 1H NMR (499.84 MHz, CD2Cl2): δ = 0.99 (s, J  = 4.0 Hz, 3H), 1.25 (m, 4H) 
,1.53 (d, J  = 11 Hz, 3H), 1.59 (s, 1H), 2.24 (m, 1H), 2.46 (t, J  = 6.0 Hz, 1H), 2.84 (d, J  = 7.9 Hz, 
2H), 3.00 (m,  1H), 3.34 (m, 1H), 3.47 (d, J = 11 Hz, 1H), 3.65 (m, 1H), 3.75–3.81 (m, 2H), 4.11 
(dd, J  = 2, 14.5 Hz, 1H), 4.15 (m, 1H), 6.42 (m, 1H), 6.95 (m, 1H), 7.55(m, 1H), 8.73 (m, 1H), 
11.5 (m, 1H). 13C NMR (126.9 MHz CD2Cl2): δ = 11.9, 14.3, 14.4, 22.5, 24.9, 26.8, 29.0, 29.1, 
36.6, 52.0, 53.2, 62.0, 64.4, 68.0, 80.2, 80.2, 80.3, 84.2, 84.3, 84.8, 84.9, 85.0, 115.0, 138.4, 151.0, 
164.1, 165.2, 200.0, 220.1, 220.8.ESI MS (m/z) calculated for C17H26N5O5  [M+H], 379.1; found 
379.0. 
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5’ hydroxy 3’-O-(spermineoethyl) thymidine [3.14]: A solution of 3% TCA in DCM (10 mL) 
was added dropwise at room temperature to [3.9)] (100 mg, 0.129 mmol). The reaction was 
continued for 3 h until complete consumption of starting material was detected by TLC. The crude 
product was extracted in DCM/water and the aqueous phase was isolated, freeze-dried and 
lyophilized to dryness. The crude product was purified by silica gel column chromatography 
(EtOAc:Petroleum ether, 6:4 v/v) to obtain >99% of a white foamy product. m.p. 79 °C.  [𝛼]589
22.8 
+29.5 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm-1) = 2836.3, 
2730.4, 2450.5, 1744.8, 1631.1, 1335.8, 1249.5, 832.6, 741.6, 675.7. 1H NMR (499.9 MHz, 
CD2Cl2):  δ = 0.99 (m, 3H), 1.30 (t, J  = 10.5 Hz, 3H) , 1.38 (m, 8H), 1.48 (d, J  = 10.0 Hz, 3H), 
1.57 (s, 1H), 2.23 (m, 2H), 2.46 (t, J  = 6.0 Hz, 1H), 2.53 (m, 8H), 2.81 (d, J  = 8.0 Hz, 3H), 3.91 
(m, 1H), 3.99 (d, J = 11 Hz, 2H), 4.11 (dd, J  = 2, 12.5 Hz, 2H), 4.21 (d, J  = 5.0 Hz, 2H), 6.28 (m, 
1H), 6.95 (m,1H), 11.2 (s, J  = 12.5 Hz, 1H), 13C NMR (126.9 MHz, CD2Cl2): δ = 15.4, 60.7, 61.0, 
65.9, 65.8, 77.71, 79.6, 81.1, 92.8, 97.7, 107.2, 110.0, 110.9, 112.7, 113.5, 227.3. ESI MS (m/z) 
calculated for C22H43N6O5  [M+H], 470.3; found 469.3. 
5’-hydroxy 3’-O-(1,3-diamineoethylpropane) thymidine [3.15]: A solution of 90% TFA in 
DCM (3 mL) was added dropwise at room temperature to [3.10] (100 mg, 0.134 mmol). The 
reaction was continued for 40 min, until complete consumption of starting material was detected 
by TLC. The crude product was extracted in DCM/water and the aqueous phase was isolated, 
freeze-dried and lyophilized to dryness. The crude product was purified by silica gel column 
chromatography (EtOAc:Petroleum ether, 6:4 v/v) to obtain 56% of a white foamy product. m.p. 
80 °C.  [𝛼]589
22.6 -4.4 (c 0.01, DCM). Rf = 0.10 (EtOAc–Petroleum ether, 6:4). IR (KBr) υmax (cm-1) 
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= 3514.2, 1791.0, 1771.6, 1721.0, 1710.6, 1678.3, 1635.6, 1608.6, 1557.9, 1540.9, 1511.6, 1422.5, 
1365.6, 1222.6, 1177.7, 1092.6, 831.4, 766.2, 549.8. 1H NMR (499.9 MHz, CD2Cl2): δ = 1.22 (t, 
J  = 7 Hz, 2H), 1.24 (s, 4H),  1.60 (bs, 2H), 2.1 (s, 3H), 2.14 (d, J  = 12.5 Hz, 1H), 2.82 (s, 3H), 
3.50 (s, 1H), 3.71 (s, 1H), 4.25 (m, 6H), 4.20 (d, J = 4.0 Hz, 1H), 5.98 (t, J  = 12.5 Hz, 1H), 10.0 
(s, 1H), 11.6 (s, 1H). 13C NMR (126.9 MHz, CD2Cl2): δ = 13.1, 13.2, 22.5, 24.2, 26.9, 29.0, 29.3, 
30.9, 36.6, 52.1, 53.2, 62.0, 65.0, 80.0, 80.5, 84.2, 84.3, 84.8, 84.9, 99.2, 100.0, 110.0, 138.3, 
145.4, 162.0, 198.1, 206.2, 208.9, 210.7. ESI MS (m/z) calculated for C15H27N4O5  [M+H], 343.1; 
found 343.2. 
5’-carboxy 3’-O-(methylaminoethyl) thymidine [3.16]: To a solution of [3.11] (500 mg, 1.67 
mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (45.4 mg, 
0.241 mmol), and iodobenzene diacetate (BAIB) (682 mg, 2.29 mmol) at room temperature. After 
the mixture was stirred for 2 h, MeCN:H2O (1:1 v/v, 530 µL) was added to the reaction mixture 
and stirred for 24 h. The crude product was extracted in DCM/water and the aqueous phase was 
isolated, freeze-dried and lyophilized to dryness. The crude product was purified by flash 
chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as white powder in 62% 
yield. M.p= 79°C. [𝛼]589
22.6 = 143.5 (c 0.01, DCM), Rf = 0.10 (CHCl3: MeOH 9:1 v/v). IR (KBr) 
υmax (cm-1)=  2951.0, 2586.9, 1868.5, 1843.9, 1754.1, 1643.0, 1471.3, 1368.0, 1343.1, 1252.1, 
1117.6, 839.9, 743.7, 679.1. 1H NMR (499.9 MHz, DMSO): δ= 1.19 (t, J  = 14.0 Hz, 3H), 1.56 (t, 
J  = 4 Hz, 3H), 2.70-2.81 (m, 7H), 3.30-3.35 (m, 1H), 3.52 (bs, 1H), 3.98-4.05 (m, 2H), 4.42-4.47 
(m, 1H), 4.49 (d, J  = 2 Hz, 1H), 6.23 (m, 1H), 9.10 (s, 1H), 11.24 (bs, 1H). 13C NMR (129.69 
MHz, DMSO-d6): δ= 11.0, 12.3, 21.5, 39.7, 56.7, 60.1, 62.3, 74.6, 80.1, 82.6, 83.9, 110.1, 113.6, 
116.8, 128.8, 129.7, 136.7, 144.1, 150.2, 159.8, 162.6, 170.1, 201.9. ESI MS (m/z) calculated for 
C13H19N3O6 [M+], 313.1; found 313.0. 
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5’-carboxy 3’-O-(octylaminoethyl) thymidine [3.17]: To a solution of [3.12] (500 mg, 1.26 
mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (36.2 mg, 
0.241 mmol), and iodobenzene diacetate (BAIB) (742 mg, 2.30 mmol) at room temperature. After 
the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 530 µL) was added to the reaction 
mixture and stirred for 24 h. The crude product was extracted in DCM/water and the aqueous phase 
was isolated, freeze-dried and lyophilized to dryness. The crude product was purified by flash 
chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as white powder in 29% 
yield. M.p= 82°C. [𝛼]589
22.6 = -8.25 (c 0.01, DCM), Rf = 0.10 (CHCl3: MeOH 9:1 v/v). IR (KBr) 
υmax (cm-1)=  2934.3, 1791.6, 1658.7, 1456.3, 1364.5, 1270.7, 1133.2, 894.9, 825.1, 733.7, 669.1. 
1H NMR (499.9 MHz, DMSO): δ= 1.20 (t, J  = 11.0 Hz, 1H), 1.60 (m, 17H), 2.40-2.56 (m, 4H), 
2.60-2.90 (m, 3H), 3.28-3.59 (m, 1H), 3.63 (d, J  = 12 Hz, 1H), 4.01-4.05 (m, 2H), 4.44-4.45 (m, 
1H), 6.23 (s, 1H), 6.82 (s, 1H), 9.37 (s, 1H), 11.25 (bs, 1H). 13C NMR (125.69 MHz, DMSO-d6): 
δ= 13.2, 39.5, 39.6, 58.2, 62.1, 64.8, 80.2, 83.2, 84.4, 109.0, 112.8, 115.6, 117.8, 131.8, 134.8, 
139.0, 142.6, 162.8, 171.4, 179.9, 175.8, 194.2, 198.2, 204.8. ESI MS (m/z) calculated for 
C14H33N3O6 [M+], 411.2; found 411.9. 
5’-carboxy 3’-O-(histamineoethyl) thymidine [3.18]: To a solution of [3.13] (500 mg, 1.32 
mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (36.2 mg, 
0.241 mmol), and iodobenzene diacetate (BAIB) (742 mg, 2.298 mmol) at room temperature. After 
the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 530 µL) was added to the reaction 
mixture and stirred for 24 h. The crude product was extracted in DCM/water and the aqueous phase 
was isolated, freeze-dried and lyophilized to dryness. The crude product was purified by flash 
chromatography (CHCl3:MeOH 9:1 v/v) in >99% yield. M.p= 85°C. [𝛼]589
22.6 = -7.69 (c 0.01, 
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DCM), Rf = 0.10 (CHCl3: MeOH 9:1 v/v). IR (KBr) υmax (cm-1)=  2950.5, 1843.9, 1758.3, 1665.3, 
1471.5, 1388.3, 1339.4, 1230.7, 1118.7, 1014.6, 835.9, 737.4, 676.3. 1H NMR (499.84 MHz, 
DMSO- d6): δ = 0.89 (t, J  = 4.0 Hz, 1H), 1.25 (m, 3H) , 1.60 (s, 1H), 2.22 (m, 1H), 2.83 (d, J  = 5 
Hz, 2H), 3.02 (m,  1H), 3.34 (m, 1H), 3.72 (m, 7H), 4.14 (dd, J  = 14.5 Hz, 1H), 4.19 (m, 1H), 
6.15 (m, 1H), 7.25(m, 1H), 9.0 (s, 1H), 11.18 (bs, 1H). 13C NMR (125.69 MHz, DMSO-d6): δ= 
10.9, 37.3, 54.6, 63.9, 69.7, 79.0, 83.7, 84.4, 86.6, 110.2, 113.2, 116.1, 126.9, 127.9, 128.2, 130.1, 
135.0, 135.5, 135.7, 135.8, 145.0, 150.4, 151.7, 158.9, 163.4, 179.2, 204.8. ESI MS (m/z) 
calculated for C17H23N5O6 [M-H], 393.4; found 392.1. 
5’-carboxy 3’-O-(spermineoethyl) thymidine [3.19]: To a solution of [3.14] (500 mg, 1.06 
mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (36.2 mg, 
0.241 mmol), and iodobenzene diacetate (BAIB) (742 mg, 2.23 mmol) at room temperature. After 
the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 530 µL) was added to the reaction 
mixture and stirred for 24 h. The crude product was extracted in DCM/water and the aqueous phase 
was isolated, freeze-dried and lyophilized to dryness. The crude product was purified by flash 
chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as white powder in 92% 
yield. M.p= 89°C. [𝛼]589
25  = +63.25 (c 0.01, DCM), Rf = 0.10 (CHCl3: MeOH 9:1 v/v). IR (KBr) 
υmax (cm-1)=  2949.0, 1868.5, 1843.9, 1665.7, 1472.0, 1366.5, 1332.4, 1231.5, 1118.7, 1089.1, 
1059.2, 1014.5, 975.8, 635.8, 734.7, 678.1. 1H NMR (499.8 MHz, DMSO-d6): δ = 0.98 (m, 1H), 
1.30 (t, J  = 10.5 Hz, 2H) , 1.38 (m, 4H), 1.48 (d, J  = 10.0 Hz, 3H), 1.57 (s, 1H), 2.23 (m, 1H), 
2.46 (t, J  = 6.0 Hz, 1H), 2.53 (m, 7H), 2.81 (d, J  = 8.0 Hz, 1H), 3.91 (m, 4H), 3.99 (d, J = 11 Hz, 
3H), 4.11 (dd, J  = 12.5 Hz, 4H), 4.21 (d, J  = 5.0 Hz, 2H), 6.28 (m, 1H), 6.95 (m,3H), 11.2 (s, J  = 
12.5 Hz, 1H), 13.0 (m, 1H). 13C NMR (125.70 MHz, DMSO-d6): δ= 12.1, 14.5, 21.2, 55.5, 60.2, 
64.2, 74.7, 80.4, 83.3, 84.1, 84.2, 86.5, 110.2, 113.75, 128.1, 128.4, 130.2, 135.6, 135,8, 136.0, 
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145.1, 150.8, 158.6, 164.1, 170.8, 201.1ESI MS (m/z) calculated for C22H40N6O6 [M-H], 484.3; 
found 483.3. 
5’-carboxy 3’-O-(1,3-diamineoethylpropane) thymidine [3.20]: To a solution of [3.15] (500 
mg, 1.46 mmol) in CH2Cl2 (1 mL) was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) 
(36.2 mg, 0.241 mmol), and iodobenzene diacetate (BAIB) (742 mg, 2.298 mmol) at room 
temperature. After the mixture was stirred for 2 h, a mixture of MeCN:H2O (1:1 v/v, 530 µL) was 
added to the reaction mixture and stirred for 24 h. The crude product was extracted in DCM/water 
and the aqueous phase was isolated, freeze-dried and lyophilized to dryness. The crude product 
was purified by flash chromatography (CHCl3:MeOH 9:1 v/v). The pure product was obtained as 
white powder in 90% yield. M.p= 80°C. [𝛼]589
22.8 = -4.4 (c 0.01, DCM), Rf = 0.10 (CHCl3: MeOH 
9:1 v/v). IR (KBr) υmax (cm-1)=  2933.9, 1678.2, 1365.8, 1179.3, 1131.2 1H NMR (499.9 MHz, 
DMSO-d6): δ = 1.25 (t, J  = 11.5 Hz, 1H), 1.24-1.59 (m, 8H), 2.15 (s, 3H), 2.19 (d, J  = 6 Hz, 1H), 
2.80 (bs, 2H), 3.51 (s, 2H), 3.70 (s, 1H), 4.15-4.20 (m, 1H), 4.42 (bs, 2H), 6.0 (t, J  = 8 Hz, 1H), 
11.62 (s, 1H), 13.25 (bs, 1H). 13C NMR (125.70 MHz, DMSO-d6): δ= 12.9, 14.3, 22.5, 26.2, 26.6, 
29.1, 29.5, 31.7, 83.2, 84.4, 85.9, 108.9, 108.9, 138.6, 150.9, 164.4, 173.4.  ESI MS (m/z) 
calculated for C15H24N4O6Na [M+Na], 379.1; found 379.0. 
Solid phase bioconjugation. 
 Solid-phase bioconjugation of peptide nucleolipids (3.22-3.31) were performed on an oil 
bath reaction apparatus with a stirring block. The peptide-bound Rink amide poly (ethylene glycol) 
resin (Nova PEG, 0.47 mmol/g) 3.21, was added into a microglass tube and slowly agitated with 
DMF (500 µL) at 60 ºC. Nucleolipids (3.16-3.20, 3 eq.) were added in DMF (500 µL) along with 
NMM (6 eq.) and HCTU (3 eq.). The reaction mixture was preactivated for 7 min before being 
slowly added to the resin-bound peptide and agitated for 14 h at 60 ºC. Following coupling, the 
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resin was washed with MeOH, DMF and DCM (3x15 mL) followed by deprotection of the Fmoc 
protecting group (30 min) with 20% piperidine in DMF. The resin was then washed (MeOH, DMF 
and DCM) and dried with N2(g). Labeling of the Ahx-peptide N-terminus with fluorescein 
isothiocyanate (FITC, 1.1 eq.) in pyridine:DMF:DCM (12:7:5 v/v/v) was accomplished in the 
dark, overnight at room temperature. Following synthesis, peptide cleavage from the solid support 
and deprotection of the side-chain protecting groups were accomplished with concentrated 
trifluoroacetic acid (TFA, 95%) with minimal addition (5%) of reaction scavengers (i.e. H2O, 
triethylsilane). The cleavage and deprotection reaction was completed in 2 hrs at room 
temperature. Peptide-nucleolipid samples (3.22-3.31) were concentrated, precipitated in cold 
ether, and isolated as white pellets for LC/MS analyses and purification. 
Characterization of peptides by LC/MS: 
Crude peptide-nucleolipid samples were dissolved in MeOH/H2O for LCMS analyses. 
Sample analyses were performed on an Agilent 1100 series ESI-LCMS with single quadrupole 
mass analyzer and LC conditions which used a linear binary gradient (2-80% MeOH/H2O, 0.1% 
FA, over 25min). Analytical RP-HPLC was performed using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) using a linear binary gradient, 20-80% or 2-82% 
MeCN/H2O, 0.1%FA, over 17 min at 25°C, with a 1 mL/min flow rate and detection at 220 nm 
and 260 nm. Samples collected after purification were lyophilized to a white solid and re-dissolved 
in 50:50 v/v H2O:MeOH to confirm purity and identity by LCMS analyses. 
Circular Dichroism (CD) Spectroscopy:                                                        
Samples were prepared 12-16 hr. ahead of time in H2O:TFE (50:50, v/v) and stored at 5 
ºC. CD spectra were collected as an average of 3 scans on an Olis Circular Dichroism (CD) 
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Spectrophotometer (Model: 24994 Rapid Scanning Monochromator, online instrument system) 
from 260-190 nm, using 1 nm bandwidth and 0.5 min step size at 25 oC. Samples were blank 
corrected, the data was smoothed and converted to molar ellipticity values from the equation [θ] = 
θ /cl, where θ is the molar ellipticity (mdeg), c is the molar concentration of the peptides (12.5 
µM) and l is the path length of the cell (1 cm). The data was imported into Microsoft Excel and 
the CD spectra were plotted in terms of molar ellipticity vs wavelength. 
UV/Vis Spectroscopy. 
 The final concentrations of the peptide solutions was determined by UV/Vis 
spectrophotometry at 214 nm ( value of peptides and calculated from the equation:              
 214 = (peptidebond)(npeptidebonds) + Σ (aminoacid(i))(naminoacid(i)).  
The analyses were conducted on an 8452A Diode Array Spectrophotometer from OLIS, with 
wavelength range set from 190 – 600 nm with maximum absorption collected at 220 and 260 nm 
in addition to 490 nm for the FITC-labeled peptides. Peptide concentrations were standardized at 
12.5 M. 
Cell Viability. 
To evaluate the MM1S cells’ viability following treatment with the synthetic peptide-nucleolipid 
bioconjugates, 3.22-3.31, the MM1S cells were incubated for 24 h in a 24 well plate, at 50,000 
viable cells/well. MM1S cells were left untreated, and treated with the synthetic peptide-
nucleolipid bioconjugates, 3.22-3.31, (2.5 M) at 37°C in 5% CO2 humidified air. Cells were then 
collected and washed with FACS buffer, centrifuged, and suspended in Guava Nexin Reagent® 
(100 L/tube, from EMD Millipore). Following incubation (20 min) at room temperature in the 
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dark, the MM1S cells were analyzed for early and late apoptotic events by flow cytometry 
following the vendor instructions.  
 
3.8 REFERENCES: 
 
1) Allain, V.; Bourgaux, C.; Couvreur, P. Nucleic Acids Res. 2012, 40, 1891-1903. 
2) Gissot, A.; Camplo, M.; Grinstaff, M.W.; Barthélémy, P. Org. Biomol. Chem. 2008, 6, 1324-
1333. 
3) Rosemeyer, H. Chem. Biodiv., 2005, 2, 977-1063. 
 
4) Patel, P.; Hanawa, E.; Yadav, R.; Samuni, U.; Marzabadi, C.; Sabatino, D. Bioorg. Med. 
Chem. Lett., 2013, 23, 5086-5090. 
 
5) Simeone, L.; Milano, D.; De Napoli, L.; Irace, C.; Di Pascale, A.; Boccalon, M.; Tecilla, 
P.; Montesarchio, D. Chemistry 2011, 17, 13854-13865. 
 
6) Simeone, L.; Irace, C.; Di Pascale, A.; Ciccarelli, D.; D'Errico, G.; Montesarchio, D. Eur. J. 
Med. Chem. 2012, 57, 429-440. 
 
7) Patil, S.P.; Yi, J.W.; Bang, E.K.; Jeon, E.M.; Kim, B.H. Med. Chem. Commun., 2011, 2, 505-
508. 
8) Yang, H.W.; Yi, J.W.; Bang, E.K.; Jeon, E. M.; Kim, B. H. Org. Biomol. Chem., 2011, 9, 
291-296.  
9) Latxague, L.; Dalila, M.J.; Patwa, A.; Ziane, S.; Chassande, O.; Godeau, G.; Barthelemy, P. 
Chimie, 2012, 15, 29-36.  
 
10) Campins, N.; Dieudonne, P.; Grinstaff, M.W.; Barthelemy, P. New J. Chem., 2007, 31, 1928–
1934. 
 
 
11) Moreau, L.; Barthelemy, P.; El Maataoui, M.; Grinstaff, M.W. J. Am. Chem. Soc., 2004, 126, 
7533–7539. 
 
12) Chabaud, P.; Camplo, M.; Payet, D.; Serin, G.; Moreau, L.; Barthelemy, P.; Grinstaff, M.W.; 
Bioconjug. Chem., 2006, 17, 466–472. 
 
 
110 
 
13) Moreau, L.; Barthelemy, P.; Li, Y.; Luo, D.; Prata, C. A. H.; Grinstaff, M.W. Mol. BioSyst., 
2005, 1, 260–264. 
 
14) Barthelemy, P.; Prata, C. A. H.; Filocamo, S. F.; Immoos, C. E.; Maynor, B. W.; Hashmi, S. 
A. N.; Lee, S. J.; Grinstaff, M.W. Chem. Comm., 2005, 10, 1261–1263.  
 
 
15) Arigon, J.; Prata, C. A. H., Grinstaff, M. W.; Barthelemy, P. Bioconjug. Chem., 2005, 16, 
864–872. 
 
16) Milani, S.; Bombelli, F.B.; Berti, D.; Hauss, T.; Dante, S.; Baglioni, P. Biophys. J., 2006, 90, 
1260–1269. 
 
17) Khiati, S.; Pierre, N.; Andriamanarivo, S.; Grinstaff, M.W.; Arazam, N.; Nallet, F.; 
Navailles, L.; Barthelemy, P. Bioconjug. Chem., 2009, 20, 1765–1772. 
 
18) Bombelli, F.B.; Berti, D.; Almgren, M.; Karlsson, G.; Baglioni, P. J. Phys. Chem, 2006, 110, 
17627–17637. 
 
 
19) Yanagawa, H.; Ogawa, Y.; Furuta, H.; Tsuno, K. J. Am. Chem. Soc. 1989, 111, 4567–4570. 
 
20) Horton, K.L.; Stewart, K.M.; Fonseca, S.B.; Guo, Q.; Kelley, S.O. Chem. Biol. 2008, 15, 
375-382. 
 
 
21) Andersen, H.H.; Elberling, J.; Arendt-Nielsen, L. Acta. Derm. Venereol., 2015, 95, 771–775. 
 
22) Julian, M.; Hernandez, A.; Maurras, A.; Puget, K.; Amblard, M.; Martinez, J.; Subra, G. 
Tetrahedron Lett. 2009, 50, 260-263. 
 
23) Rana, N., Huang, S.; Patel, P.; Samuni, U.; Sabatino, D. Bioorg. Med. Chem. Lett., 2016, 26, 
3567–3571.  
  
24) García-Ramos, Y.; Paradís-Bas, M.; Tulla-Puche, J.; Albericio, F.; J. Pept. Sci. 2010, 16, 
675-678. 
 
25) Dıaz-Mochon, J. J.; Bialy, L.; Bradley, M. Org. Lett., 2004, 6, 1127–1129.  
  
26) Ozdirekcan, S.; Nyholm, T. K.; Raja, M.; Rijkers, D. T.; Liskamp, R. M.; Killian, J. A. 
Biophys. J. 2008, 94, 1315-1325. 
 
27) Epand, R.; Shai, Y.; Segrest, J. P.; Anantharamaiah, G. M.  Pept. Sci. 1995, 37, 319-338. 
 
28) Greenstein, S.; Krett, N.L.; Kurosawa, Y.; Ma, C.; Chauhan, D.; Hideshima, T.; Anderson, 
K.C.; Rosen, S.T. Exp. Hematol. 2003, 31, 271-282. 
111 
 
 
29) Demo, S.D.; Masuda, E.; Rossi, A.B.; Throndset, B.T.; Gerard, A.L.; Chan, E.H.; Armstrong, R.J.; 
Fox, B.P.; Lorens, J.B.; Payan, D.G.; Scheller, R.H.; Fisher, J.M. Cytometry 1999, 36, 340–348. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
CHAPTER 4. CONCLUSIONS, FUTURE WORK AND CONTRIBUTIONS TO 
KNOWLEDGE 
4.1 CONCLUSIONS MADE IN THIS THESIS 
4.1.1 SYNTHESIS, CHARACTERIZATION AND ANTI-CANCER ACTIVITY OF A 
PEPTIDE-NUCLEOLIPID BIOCONJUGATE 
 In Chapter 2, the design, synthesis and characterization of a new class of “killer” peptide 
nucleolipid bioconjugate was described for anti-cancer applications. These research objectives 
were accomplished by developing a solution-phase synthesis strategy for making the requisite 5’- 
carboxy 3’-hexadecylamine thymidine nucleolipid (Scheme 2.1). The key step in this synthetic 
approach was based on a reductive amination reaction which condensed hexadecylamine onto the 
3’-aldehyde-derived thymidine building block. This strategy was envisioned as an entry point for 
coupling a variety of alkyl, aryl and heterocyclic amines in order to generate functionally diverse 
nucleolipids. In this proof-of-concept study, the 3’-hexadecylamine-derived nucleolipid was 
synthesized in good yields and converted to the 5’-carboxy-derived nucleolipid following 5-
detritylation and oxidation reactions. The final nucleolipid product was characterization by NMR, 
IR spectroscopy and mass spectrometry in order to validate identity and compound purity. 
 This thymidine-derived nucleolipid was rationally designed and developed for conjugation 
with the pro-apoptotic peptide D-(KLAKLAK)2 sequence (Figure 2.1). This so-called “killer” 
peptide has shown the ability to induce bacterial cell death, with limited toxicity observed in 
mammalian cells [1]. In order to improve the cytotoxic activity of the D-(KLAKLAK)2 sequence 
towards malignant mammalian cell types, such as cancer, the amphiphilic nucleolipid was 
anticipated to enhance cell permeability and mitochondria localization of the D-(KLAKLAK)2-
AK sequence for potentiating its anti-cancer activity. The native D-(KLAKLAK)2-AK and 
palmitamide derived sequences were made as controls using solid phase peptide synthesis. In the 
case of the palmitamide-derived sequence, an orthogonally protected Lys(Dde) was unmasked 
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using buffered hydroxylamine and the liberated -amino group was reacted with palmitic acid 
using HCTU coupling conditions to afford the C-terminal palmitamide derived D-(KLAKLAK)2-
AK. The HCTU-based coupling conditions were also used to generate the nucleolipid derived D-
(KLAKLAK)2-AK sequence. These sequences also contained N-terminal modifications, including 
the incorporation of the Ahx linker and FITC. The peptide bioconjugates were isolated in sufficient 
yields (10-33%) and purities (≥96%) for structure-activity relationship studies. 
 Comparison of retention times of the peptide conjugates with the native sequence indicated 
that conjugation of the D-(KLAKLAK)2-AK sequence with palmitic acid and nucleolipid 
produced more hydrophobic, retained sequences on the C18 reverse-phase HPLC column (Figure 
2.2. B). Moreover, UV-Vis absorption studies validated the characteristics absorptions for the 
peptide (220 nm) and nucleolipid (260 nm) (Figure 2.2 C).  CD spectroscopy was used to study 
the secondary structures of the conjugates in comparison to the native sequence.  Distinct α-helical 
secondary structures were observed for all samples in a H2O:TFE solvent system indicating that 
conjugation retains the helical peptide character of the sequence (Figure 2.2D and Table 2.2). 
DLS and TEM studies were used to confirm the self-assembly of the peptide high-ordered 
nanostructures, presumably due to the amphiphilic nature of the sequence (Figure 2.3). Thus, the 
amphiphilic peptide bioconjugates were found to retain the structure (-helix) characteristics of 
the native sequences, while fine-tuning its polar properties for biological action in malignant 
cancer cells. We hypothesized that the positively charged, amphiphilic -helical peptide 
conjugates would display enhanced cell permeability and mitochondria localization leading to 
toxicity in cancer cells. In order to test this hypothesis, the anti-cancer activity of the peptide 
conjugates were examined relative to the native sequence.    
114 
 
A 60 cancer cell line screen was performed at the National Cancer Institute, testing the 
anti-proliferative properties of the peptides dosed at a single concentration. In this screen, the 
amphiphilic peptide bioconjugates were found to be more active than the native D-(KLAKLAK)2-
AK sequence, especially in a selected panel of non-small cell lung carcinoma (Table 2.3, Figures 
2.4-2.7). The A549 lung cancer cell line was found to be the most sensitive, with the nucleolipid-
derived sequence exhibiting the greatest cytotoxicity followed by the palmitamide and the native 
peptide sequence. Thus, conjugation of the D-(KLAKLAK)2-AK sequence with the amphiphilic 
nucleolipid has served to potentiate the anti-cancer activity of the so-called “killer” peptide 
sequence [2]. A structure-activity relationship study was developed in Chapter 3 in order to explore 
the influence of nucleolipid modifications on the anti-cancer activity of the D-(KLAKLAK)2-AK 
sequence.   
 
4.1.2 DIVERSITY ORIENTED SYNTHESIS OF PEPTIDE NUCLEOLIPID 
BIOCONJUGATES FOR STRUCTURE-ACTIVITY RELATIONSHIP STUDIES 
 In Chapter 3, a new diversity oriented synthesis approach is described for the generation 
of modified nucleolipids and their incorporation within the native D-(KLAKAK)2-AK sequence. 
These methods are important for the generation of new peptide nucleolipid bioconjugates that may 
serve as bifunctional probes for exploring the influence of nucleolipid modification on the anti-
cancer activity of the D-(KLAKAK)2-AK sequence. The diversity oriented synthesis approach 
described in chapter 3 is based on our existing reductive amination methodology [2]. Extension of 
the substrate scope related to this method allowed for the condensation of alkylamines, 
polyamines, and heterocyclic amines onto the 3’-aldehyde derived thymidine precursor (Figure 
3.5). This two-step one pot reaction allowed for the generation of structurally diverse nucleolipids 
115 
 
which were subsequently converted into their reactive 5’-carboxy derived nucleolipids following 
our previously described detritylation and oxidation conditions [2]. Each nucleolipid was 
characterized by a combination of 1H, 13C NMR, IR spectroscopy and mass spectrometry in order 
to confirm identities and purities. The isolated 5’-carboxy derived nucleolipids were incorporated 
at the Lys C-terminus of the D-(KLAKAK)2-AK sequence by the HCTU-mediated coupling 
conditions previously described [2]. Furthermore, peptides were generated with and without the 
N-terminal FITC for exploring structure-activity relationships against cellular tumor targets 
(Figure 3.6).  
 The isolated peptide-nucleolipid bioconjugates were analyzed and purified by RP HPLC. 
The identities of the pure bioconjugates were confirmed by LC-MS for exploring our structure-
activity relationship studies. The amphiphilic properties of the peptide-nucleolipid bioconjugates 
were initially explored by RP-HPLC (Figure 3.7). In this study, the alkylamine and polyamine 
derived nucleolipids were found to impart greater hydrophobicity onto the D-(KLAKAK)2-AK 
sequence when compared to the histamine-derived nucleolipids. CD spectroscopy was then used 
to evaluate the secondary structures (if any) of the peptides in H2O:TFE. The combination of 
H2O:TFE served to mimic the amphiphilic lipid bilayer microenvironment that may stabilize 
peptide secondary structures. The structurally diverse nucleolipids were found to retain -helical 
peptide secondary structures, albeit, with varying effects on (Percentage of) helical character 
(Figure 3.9).  
 The biological evaluation of the small library of peptide nucleolipid bioconjugates has been 
tested on the HepG2 hepatoblastoma cell culture. In this assay, a Guava Nexin® Reagent (EMD 
Millipore) was used to assess early and late-stage apoptosis by flow cytometry [3]. The results 
revealed no signifncant populations in early and late stage apoptotic events for the HepG2 cells 
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when treated with the synthetic bioconjugates, (Figure 3.10). These results are preliminary and 
additional biological testing is anticipated to confirm the capabilities of structurally diverse 
nucleolipids to potentiate the cancer cell death effects of the D-(KLAKAK)2-AK sequence. 
Furthermore, the FITC-labeled bioconjugates may provide important mechanistic information 
related to cell permeability and mitochondrial localization for anti-cancer activity. In a related 
study, the lead nucleolipid-derived D-(KLAKAK)2-AK sequence may be extended with cancer-
targeting peptide sequences in order to facilitate selective anti-cancer activity. The latter is a 
current focus of our on-going research work for generating potent and selective anti-cancer 
peptides.  
4.2 PRELIMINARY STUDIES AND FUTURE WORK TOWARDS THE DEVELOPMENT 
OF A CANCER-TARGETING PEPTIDE-NUCLEOLIPID BIOCONJUGATE 
4.2.1 RATIONAL DESIGN 
 The Pep42 cancer-targeting peptide has been a cornerstone sequence in our research group 
for the development of selective anti-cancer approaches [4]. Pep42, was selected by Janda and co-
workers as a short, cyclic peptide sequence capable of binding to and internalizing within cancer 
cells that express GRP78 on the cell surface [5]. Considering that GRP78 functions as an 
oncoprotein signaling tumor initiation, proliferation, invasion and drug resistance, it has been 
classified as a therapeutically relevant biomarker in cancer [6]. Furthermore, GRP78 is 
overexpressed on the cell surface of many transformed primary tumors, but not on normal, healthy 
cells making the identification of cell surface GRP78 ligands of critical importance for the 
development of cancer-targeting strategies. In our approach, a lead nucleolipid-derived D-
(KLAKAK)2-AK sequence is extended at the N-terminus with the Pep42 sequence, 
CTVALPGGYVRVC,, followed by the incorporation of the aminohexanoic acid linker (AHx) and 
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fluorescein isothiocyanate (FITC). Additionally, poly(ethylene) glycol spacers (0, 3, 6, 12) may 
be introduced in between the Pep42 and D-(KLAKAK)2 sequence to provide spatial control in 
between the bifunctional peptide sequences and to also help promote aqueous solubility and 
biocompatibility. A structure representation of a first generation FITC-Ahx-Pep42-D-
(KLAKAK)2-AK-nucleolipid conjugate is described in Figure 4.1.     
 
Figure 4.1. Rational design of the GRP78-targeting FITC-Ahx-Pep42-D-(KLAKAK)2-AK-
nucleolipid conjugate. 
 
 
4.2.2. SYNTHESIS 
Working alongside Adah Beck, a first year undergraduate student working in the laboratory 
of Dr. David Sabatino in the Department of Chemistry and Biochemsitry, a synthesis strategy for 
the desired bioconjugate was designed and developed. Fmoc-based solid phase peptide synthesis 
was used for the preparation of the GRP78-targeting FITC-Ahx-Pep42-D-(KLAKAK)2-AK-
nucleolipid conjugate. The peptide sequence was generated on a Rink Amide NovaPEG resin. At 
the C-terminus, the Lys(Dde) residue was incorporated and selectively deprotected on solid phase 
for the coupling of the carboxy-derived nucleolipid. HCTU-coupling conditions were once again 
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used to effectively couple the nucleolipd and the Fmoc-amino acids on solid phase. The first 
representative example of the Pep42- D-(KLAKAK)2-AK-nucleolipid conjugate was synthesized 
without a PEG spacer, however, the Ahx linker was incorporated at the N-terminus for FITC 
incorporation. In this final synthetic step, a portion of the peptide bound support was cleaved and 
deprotected without the FITC label, whereas, another portion of the resin was used to couple FITC 
at the N-terminus. Following cleavage and deprotection, the crude peptide bioconjugates were 
analyzed by LCMS to confirm identities and purities. Our synthetic strategy for making the 
GRP78-targeting FITC-Ahx-Pep42-D-(KLAKAK)2-AK-nucleolipid conjugate proved fruitful 
(Scheme 4.1 and Figures 4.2, 4.3) and sets the stage for making a small library of Pep42- D-
(KLAKAK)2-AK-nucleolipid bioconjugates for exploring selective and potent anti-cancer 
activities in tumors that overexpress GRP78 at the cell surface. The latter is a focal point of our 
current studies aimed towards the development of potent GRP78-targeting ligands. 
 
Scheme 4.1.  Fmoc-solid phase peptide synthesis of Pep42-D-(KLAKAK)2-AK-nucleolipid 
bioconjugates.    
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Figure 4.2. LC-MS analysis of crude AHx-CTVALPGGYVRVC-D-(KLAKLAKKLAKLAK)-
AK-Dde using a linear gradient 20-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 
Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow 
rate of 1.0 mL/min with detection at 220 nm. 
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Figure 4.3. ESI-MS analysis of crude AHx-CTVALPGGYVRVC-D-(KLAKLAKKLAKLAK)-
AK-Dde using a linear gradient 20-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 
Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow 
rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine nucleolipid, 3.22 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220nm 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 10.671 395043 98.95 133547 
2 11.608 71105 1.05 4450 
 
Figure A1. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine 
nucleolipid, 3.22 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A2. LC-MS analysis of crude AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine 
nucleolipid, 3.22 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A3. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine 
nucleolipid, 3.22 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine nucleolipid, 3.23 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220nm 
 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 10.262 1797 4.05 23666 
2 11.262 108567 95.95 33003 
 
 
Figure A4. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine 
nucleolipid, 3.23 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A5. LCMS analysis of crude AHx-D-(KLAKLAKKLAKLAK)-AK-Octcylamine 
nucleolipid, 3.23 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
135 
 
 
 
 
 
Figure A6. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine 
nucleolipid, 3.23 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine nucleolipid, 3.24 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220nm 
 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 8.998 31396 1.34 30778 
2 9.304 573102 95.01 123665 
3 10.684 188451 3.65 161128 
 
 
Figure A7. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine 
nucleolipid, 3.24 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A8. LCMS analysis of crude AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine 
nucleolipid, 3.24 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A9. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine 
nucleolipid, 3.24 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine nucleolipid, 3.25 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220nm 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 9.473 318468 1.20 1141 
2 10.826 763932 2.46 53514 
3 12.035 1193838 96.34 95167 
 
 
Figure A10. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine 
nucleolipid, 3.25 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A11. LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine 
nucleolipid, 3.25 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
141 
 
 
 
Figure A12. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine 
nucleolipid, 3.25 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-diaminopropane nucleolipid, 3.26 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220nm 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 8.749 38426 0.86 86646 
2 10.176 586519 1.20 79560 
3 10.707 296971 0.91 36979 
4 11.948 857782 97.03 97567 
 
 
Figure A13. RP-HPLC analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-
diaminopropane nucleolipid, 3.26 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A14. LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-
diaminopropane nucleolipid, 3.26 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A15. ESI-LCMS analysis of purified AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-
diaminopropane nucleolipid, 3.26 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine, 3.27 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 495nm 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 13.290 32452 100 1232 
 
 
Figure A16. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-
Methylamine nucleolipid, 3.27 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 495 nm. 
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Figure A17. LCMS analysis of crude FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Methylamine 
nucleolipid, 3.27 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 495 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
 
 
 
Figure A18. ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-
Methylamine nucleolipid, 3.27 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 495 nm. 
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine, 3.28 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220 nm 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 15.047 108239 100 9432 
 
 
Figure A19. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-
Octylamine nucleolipid, 3.28 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A20. LCMS  analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Octylamine 
nucleolipid, 3.28 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A21. ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-
Octylamine nucleolipid, 3.28 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine, 3.29 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220 nm 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 12.167 108239 50.0 2873 
2 12.573 199388 49.5 3127 
 
 
Figure A22. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-
Histamine nucleolipid, 3.29 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A23. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Histamine 
nucleolipid, 3.29 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A24. ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-
Histamine nucleolipid, 3.29 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine, 3.30 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220 nm 
 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 13.326 8348 1.4 454 
2 13.331 121470 98.6 946 
 
 
Figure A25. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-
Spermine nucleolipid, 3.30 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A26. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-Spermine 
nucleolipid, 3.30 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at 
a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A27. ESI-LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-
Spermine nucleolipid, 3.30 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-diaminopropane, 3.31 
Solvent: 2-80% MeOH (0.1% FA) over 17 min 
Detection: PDA 220 nm 
 
 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 15.036 100 140525 8938 
 
 
Figure A28. RP-HPLC analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-
diaminopropane nucleolipid, 3.31 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A29. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-
diaminopropane nucleolipid, 3.31 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A30. LCMS analysis of purified FITC-AHx-D-(KLAKLAKKLAKLAK)-AK-1,3-
diaminopropane nucleolipid, 3.31 using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 
min using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Figure A31. 1H NMR spectrum of 2.2 
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Figure A32. 13C NMR spectrum of 2.2 
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Figure A33. 1HNMR spectrum of 2.3 
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Figure A34. 13CNMR spectrum of 2.3 
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Figure A35. 1H-NMR spectrum of 2.4 
 
165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A36. 13C-NMR spectrum of 2.4 
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Figure A37. 1H-NMR spectrum of 2.5 
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Figure A38. 13C-NMR spectrum of 2.5 
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Figure A39. 1H-NMR spectrum of 2.6 
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Figure A40. 13C-NMR spectrum of 2.6 
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Figure A41. ESI-MS spectra of  D-(KLAKLAKKLAKLAK) 
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Figure A42. ESI-MS spectra of  D-(KLAKLAKKLAKLAK)-AK 
 
 
Figure A43. ESI-MS spectra of  D-(KLAKLAKKLAKLAK)-AK-Palmitamide 
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Figure A44. ESI-MS spectra of D-(KLAKLAKKLAKLAK)-AK-Nucleolipid 
 
Figure A45. ESI-MS spectra of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AK 
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Figure A46. ESI-MS spectra of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AK-Palmitamide. 
 
 
Figure A47. ESI-MS spectra of FITC-Ahx-D-(KLAKLAKKLAKLAK)-AK-Hexadecyl 
Nucleolipid 
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Sequence: Purified Crude D-(KLAKLAKKLAKLAK) 
Solvent: 2-83% MeCN (0.1% TFA) over 18 min 
Detection: PDA 220nm 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 5.727 40407 0.84 16862 
2 5.828 71105 1.49 28974 
3 6.049 108374 2.26 40163 
4 6.190 51206 1.07 20630 
5 6.835 65376 1.37 28942 
6 6.987 4448515 92.97 998144 
Figure A48. RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK) using a linear gradient 
2-83% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 column (3.9 x 
150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with 
detection at 220 nm. 
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Result and analysis: 
 Retention Time Area % Area 
1 7.528 1965904 100.00 
Figure A49. RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK) using a linear gradient 
2-83% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 column (3.9 x 
150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with 
detection at 220 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Retention Time Area % Area 
1 7.528 1965904 100.00 
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Sequence: NH2-AHx-D-(KLAKLAK)2-AK  
Solvent: 2to80MeOH (0.1%FA) over 17 min 
Detection: PDA 220nm 
Results and analysis: 
 
 
 
 
Figure A50. RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK)-AK using a linear 
gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 
mL/min with detection at 220 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Retention Time Area % Area 
1 6.460 391097 100.00 
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Sequence: NH2-AHx-D-(KLAKLAK)2-AK  
Solvent: 2-80% MeCN (0.1% FA) over 17 min 
Detection: PDA 220nm 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 4.282 1837039 100.00 200442 
Figure A51. RP-HPLC analysis of purified D-(KLAKLAKKLAKLAK)-AK using a linear 
gradient 2-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 
mL/min with detection at 220 nm. 
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Sequence: FITC-NH2-AHx-D-(KLAKLAK)2-AK  
Solvent: 2to80MeOH (0.1%FA) over 17 min 
Detection: PDA 220nm 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 10.503 536682 100.00 49875 
Figure A52. RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AK using a linear 
gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 
mL/min with detection at 220 nm. 
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Sequence: FITC-NH2-AHx-D-(KLAKLAK)2-AK  
Solvent: 2to80 MeCN (0.1%FA) over 17 min 
Detection: PDA 220nm 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 6.007 625007 100.00 85771 
Figure A53. RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AK using a linear 
gradient 2-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 
mL/min with detection at 220 nm. 
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Sequence: Purified Crude D-(KLAKLAK)2-AK-Nucleolipid  
Solvent: 2to80 MeOH (0.1%FA) over 17 min 
Detection: PDA 260nm 
Note: After 17min, column contains impurities that are also found in the blank that has not been integrated. 
 
Results and analysis: 
 Retention Time Area % Area 
1 7.991 69 0.36 
2 8.720 669 3.49 
3 11.322 18443 96.15 
 
Figure A54. RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AK-Hexadecylamine 
nucleolipid using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C 
at a flow rate of 1.0 mL/min with detection at 220 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
7
.9
9
1
8
.7
2
0
1
1
.3
2
2
A
U
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00
181 
 
Sequence: Purified Crude D-(KLAKLAK)2-AK-Nucleolipid  
Solvent: 2to80 MeCN (0.1%FA) over 17 min 
Detection: PDA 220nm 
 
Results and analysis: 
 Retention Time Area % Area 
1 6.348 70359 84.12 
2 6.680 376 0.45 
3 6.979 574 0.69 
4 7.433 12333 14.75 
 
Figure A55. RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AK-hexadecylamine 
nucleolipid using a linear gradient 2-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 
2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C 
at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: Pure FITC-D-(KLAKLAK)2-AK-Nucleolipid (FITC isomer used) 
Solvent: 20to80 MeOH (0.1%FA) over 17 min 
Detection: PDA 220 nm 
 
Results and analysis: 
 Retention Time Area % Area 
1 7.626 131930 10.30 
2 8.147 110919 8.66 
3 8.887 71872 5.61 
4 9.275 49954 3.90 
5 9.542 6980 0.55 
6 10.361 445885 34.82 
7 10.706 462856 36.15 
 
Figure A56. RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AK-
hexadecylamine nucleolipid using a linear gradient 2-80% MeOH/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: Pure FITC-D-(KLAKLAK)2-AK-Nucleolipid (FITC isomer used) 
Solvent: 20to80 MeCN (0.1%FA) over 17 min 
Detection: PDA 220 nm 
 
Results and analysis: 
 Retention Time Area % Area 
1 7.642 96124 10.93 
2 8.168 59638 6.78 
3 10.407 362857 41.25 
4 10.745 360942 41.04 
 
Figure A57. RP-HPLC analysis of purified FITC-NH2-AHx-D-(KLAKLAK)2-AK-
hexadecylamine nucleolipid using a linear gradient 2-80% MeCN/H2O (0.1% FA) over 17 min 
using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) set at a 
temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 220 nm. 
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Sequence: Pure D-(KLAKLAK)2-AK-Palmitamide 
Solvent: 20to80 MeCN (0.1%FA) over 17 min 
Detection: PDA 220 nm
Results and analysis: 
 Retention Time Area % Area Height 
1 13.869 58123 100.00 10727 
 
Figure A58. RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AK-Palmitamide using a 
linear gradient 20-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 
mL/min with detection at 220 nm. 
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Sequence: D-(KLAKLAK)2-AK-Palmitamide 
Solvent: 20to80 MeOH (0.1%FA) over 17 min 
Detection: PDA 220 nm 
 
Results and analysis: 
 Retention Time Area % Area 
1 17.650 7418305 100.00 
 
 
Figure A59. RP-HPLC analysis of purified NH2-AHx-D-(KLAKLAK)2-AK-Palmitamide using a 
linear gradient 20-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 
mL/min with detection at 220 nm. 
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Sequence: FITC-D-(KLAKLAK)2-AK-Palmitamide 
Solvent: 20to80 MeOH (0.1%FA) over 17 min 
Detection: PDA 495 nm 
 
Results and analysis: 
 Retention Time Area % Area Height 
1 15.476 42560 100.00 1086 
 
 
Figure A60. RP-HPLC analysis of purified FITC-D-(KLAKLAK)2-AK-Palmitamide using a 
linear gradient 20-80% MeOH/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 
mL/min with detection at 220 nm. 
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Sequence: FITC-D-(KLAKLAK)2-AK-Palmitamide 
Solvent: 20to80 MeCN (0.1%FA) over 17 min 
Detection: PDA 495 nm 
 
Results and analysis: 
 Retention Time Area % Area 
1 5.731 5215 100.00 
 
 
 
Figure A61. RP-HPLC analysis of purified FITC-D-(KLAKLAK)2-AK-Palmitamide using a 
linear gradient 20-80% MeCN/H2O (0.1% FA) over 17 min using a Waters 2695 Symmetry® C18 
column (3.9 x 150 mm, 5 m particle size) set at a temperature of 25 °C at a flow rate of 1.0 
mL/min with detection at 220 nm. 
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Figure A62. 1H-NMR spectrum of 3.6 
 
189 
 
 
 
 
Figure A63. 13C-NMR spectrum of 3.6 
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Figure A64. 1H-NMR spectrum of 3.7 
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Figure A65. 13C-NMR spectrum of 3.7 
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Figure A66. 1H-NMR spectrum of 3.8 
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Figure A67. 13C-NMR spectrum of 3.8 
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Figure A68. 1H-NMR spectrum of 3.9 
 
195 
 
 
 
Figure A69. 13C-NMR spectrum of 3.9 
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Figure A70. 1H-NMR spectrum of 3.10 
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Figure A71. 13C-NMR spectrum of 3.10 
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Figure A72. 1H-NMR spectrum of 3.11 
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Figure A73. 13C-NMR spectrum of 3.11 
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Figure A74. 1H-NMR spectrum of 3.12 
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Figure A75. 13C-NMR spectrum of 3.12 
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Figure A76. 1H-NMR spectrum of 3.13 
 
 
203 
 
 
Figure A77. 13C-NMR spectrum of 3.13 
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Figure A78. 1H-NMR spectrum of 3.14 
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Figure A79. 13C-NMR spectrum of 3.14 
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Figure A80. 1H-NMR spectrum of 3.15 
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Figure A81. 13C-NMR spectrum of 3.15 
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Figure A82. 1H-NMR spectrum of 3.16 
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Figure A83. 13C-NMR spectrum of 3,16 
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Figure A84. 1H-NMR spectrum of 3.17 
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Figure A85. 13C-NMR spectrum of 3.17 
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Figure A86. 1H-NMR spectrum of 3.18 
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Figure A87. 13C-NMR spectrum of 3.18 
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Figure A88. 1H-NMR spectrum of 3.19 
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Figure A89. 13C-NMR spectrum of 3.19 
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Figure A90. 1H-NMR spectrum of 3.20 
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Figure A91. 13C-NMR spectrum of 3.20 
